Syracuse University

SURFACE at Syracuse University
Theses - ALL
Winter 12-22-2021

Benzodiazepine Use and Dependence in Relation to Chronic Pain
Intensity and Pain Catastrophizing
Emma Carnes Lape
Syracuse University

Follow this and additional works at: https://surface.syr.edu/thesis
Part of the Clinical Psychology Commons

Recommended Citation
Lape, Emma Carnes, "Benzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain
Catastrophizing" (2021). Theses - ALL. 594.
https://surface.syr.edu/thesis/594

This Thesis is brought to you for free and open access by SURFACE at Syracuse University. It has been accepted for
inclusion in Theses - ALL by an authorized administrator of SURFACE at Syracuse University. For more information,
please contact surface@syr.edu.

Abstract
Benzodiazepines (BZDs), a class of sedative-hypnotic drugs, are at the center of an emerging
prescription drug crisis. From approximately 1995-2015, overdose deaths involving BZDs
quadrupled and average dose equivalents more than tripled. Specific concern has centered on
elevated rates of BZD use among individuals with chronic pain, given that BZDs are generally
not indicated for pain management. Consistent with negative reinforcement and motivational
models of substance use, desire for pain alleviation may be a salient motivator of BZD use,
particularly as individuals commonly report using BZDs for negative affect alleviation. The
present study tested cross-sectional associations between pain intensity and clinically relevant
BZD use patterns among individuals with chronic pain. We also examined the role of pain
catastrophizing, a malleable transdiagnostic factor reflecting negative cognitive-affective pain
responses. Participants were 306 adults (Mage = 38.7, 38.9% female) with chronic
musculoskeletal pain and a current BZD prescription who completed an online survey study via
Amazon Mechanical Turk. Hierarchical linear regression results indicated that pain intensity was
positively associated with past-month BZD use frequency and BZD dependence severity.
Logistic regression results indicated that greater pain intensity was associated with a 1.2 times
greater likelihood of endorsing BZD misuse behaviors. Pain catastrophizing was positively
associated with BZD dependence severity and likelihood of BZD misuse, after accounting for
pain intensity. Initial findings implicate pain/pain-related cognitive-affective processes in higherrisk BZD use, and suggest pain relief is a common, yet underrecognized, self-reported
motivation for taking BZDs. Future research should examine mechanisms underlying pain-BZD
covariation and co-use behaviors.
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Benzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain
Catastrophizing
Benzodiazepines (BZDs), a class of sedative-hypnotic drugs, represent one of the most
commonly prescribed medication types (Ashton, 2005; Guina & Merrill, 2018), with up to 13%
of adults in the United States reporting past-year BZD use (Blanco et al., 2018; Maust et al.,
2019; Olfson et al., 2015). BZDs produce anxiolytic, hypnotic, and muscle-relaxing effects
through their action on gamma-aminobutyric acid (GABA) receptor A (Griffin et al., 2013).
While insomnia and anxiety remain the most common indications for BZD prescription (Guina
& Merrill, 2018), clinical guidelines advise only short-term BZD use for insomnia (SchutteRodin et al., 2008) and recommend alternative first-line treatments for anxiety disorders
(Bandelow et al., 2014; Bandelow et al., 2017), with more recent changes in guidelines driven by
growing recognition of harms associated with BZDs (Bandelow et al., 2017).
BZD use has been termed an emerging epidemic and prescription drug crisis, with
addiction experts drawing parallels with the early days of the opioid epidemic (e.g., Lembke et
al., 2018; Limandri, 2018). Several trends suggest a growing problem and a need for action. For
example, overdose deaths involving BZDs quadrupled from the mid 1990s to 2013 (Bachhuber
et al., 2016). During approximately the same period, physician visits involving BZD prescription
doubled (Agarwal & Landon, 2019), average dose equivalents more than tripled (Bachhuber et
al., 2016), and numbers of continuing prescriptions (i.e., refills) increased (Kaufmann et al.,
2018). Recent estimates suggest that among adults reporting any past-year use of BZDs, 17%
endorse misuse (i.e., use in any manner not recommended by a physician) and 1.5% meet criteria
for BZD-related substance use disorder (Blanco et al., 2018). With growing recognition of the
risks and abuse potential of BZDs (e.g., Agarwal & Landon, 2019; Lembke et al., 2018; Votaw
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et al., 2019), there is a call to curb overprescription (Lembke et al., 2018) and elucidate
biopsychosocial factors contributing to BZD overuse and misuse (Rigg & Ford, 2014). To
inform both health policy and professional practice, it is critical to gather data on higher-risk
BZD use patterns including heavier use, misuse behaviors, and dependence (Brandt et al., 2018),
and to examine populations at particular risk for deleterious effects due to BZD use (e.g., chronic
pain; Guina & Merrill, 2018; Pergolizzi & LeQuang, 2020).
Patterns of BZD Use
BZD Misuse
BZDs are the third most commonly misused prescription or illicit substance in the United
States (Johnston et al., 2018), with approximately 17% of adults who report any past-year BZD
use also reporting misuse (Blanco et al., 2018). Prescription drug misuse may be defined as any
use without a prescription or in another way not as directed by a physician, commonly: with a
greater frequency, dose, or duration than prescribed (e.g., McCabe, 2005; Votaw et al., 2020).
Misuse encompasses several behaviors that increase risk for overdose (e.g., Jones et al., 2012),
including taking doses larger than recommended, as well as co-ingestion with opioids, alcohol,
or other substances contraindicated in the context of BZD use (Votaw et al., 2019). Additionally,
misuse can encompass use over longer time periods than prescribed, which is concerning due to
associations of longer-term BZD use with deleterious health outcomes (Ashton, 2005; Guina &
Merrill, 2018; Michelini et al., 1996), and because there is no evidence for long-term
effectiveness of BZDs even in conditions for which they have demonstrated shorter-term
efficacy (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, insomnia;
Guina & Merrill, 2018).
BZD Dependence and Substance-Related Disorders
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Individuals prescribed BZDs may develop BZD tolerance (i.e., increasing amounts
needed to achieve the same effect, or diminishing effects), physical dependence, and substancerelated disorders (Soyka, 2017). Diagnostic and Statistical Manual, Fifth Edition (DSM-5)
criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder (SHA use disorder; the category
under which BZD use disorders fall) include tolerance/dose escalation, craving, withdrawal
symptoms (e.g., acute anxiety, perceptual distortions, insomnia; Ashton, 2005), and continued
use despite persistent use-related problems (American Psychiatric Association, 2013). As with
other substance use disorders, diagnosis requires two of eleven symptoms and significant distress
and/or impairment. Recent estimates indicate that 1.5% of individuals reporting any past-year
BZD use also meet criteria for BZD-related SHA use disorder (2015-2016 National Survey on
Drug Use and Health; Blanco et al., 2018). Risk for BZD dependence and potential to develop
substance-related disorders are thought to increase in the context of frequent and longer-term use
(e.g., Soyka, 2017).
BZD Use Frequency
Taking BZDs at higher frequency (e.g., daily versus less than daily) is considered an
important indicator of higher-risk BZD use (e.g., Lembke et al., 2018; Votaw et al., 2019).
Greater frequency of prescription BZD use has been associated with greater likelihood of misuse
(McCabe et al., 2011) and maintenance of use over long-term follow-up (e.g., 3 years, 13 years;
Barnas et al., 1993; Isacson, 1997). Several prior studies have used retrospective recall of use
frequency over a given time period (e.g., past-month) as an indicator of high-risk use frequency
(Dublin et al., 2011; Holm et al., 2012; Nattala et al., 2011), and past-month days of use has
reliably been used to index current BZD use frequency (e.g., McHugh et al., 2017; Stein et al.,
2016).
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Chronic Pain and BZD Use
Chronic Pain Prevalence and Impact
Pain is defined as “an unpleasant sensory and emotional experience associated with, or
resembling that associated with, actual or potential tissue damage” (Raja et al., 2020). Chronic
pain, (i.e., pain persisting beyond expected healing time or > 3 months; Institute of Medicine,
2011; Treede et al., 2015) affects approximately 50 million adults in the United States, with 20
million reporting pain that frequently interferes with daily activities (Dahlhamer et al., 2018).
Musculoskeletal pain (i.e., pain affecting bones, joints, muscles, or ligaments/tendons; ArendtNielsen et al., 2011) accounts for the greatest proportion of persistent pain and related disability
(Badley et al., 1994; Briggs et al., 2018; Yelin et al., 2014). Pain is a leading cause of lost quality
of life (Boonstra et al., 2013; Gureje et al., 1998; Phillips, 2009) and is associated with greater
burdens of depression, insomnia, and cardiovascular disease (Fayaz et al., 2016; Goesling et al.,
2013; Herrero Babiloni et al., 2020) as well as increased mortality (Smith et al., 2018). Chronic
pain engenders substantial economic impact, costing over $250 billion in annual medical
expenses and more than $300 billion in lost productivity in the United States (Gaskin & Richard,
2012). Increasingly, scholars favor examination of pain as a multidimensional construct
including both pain intensity and pain-related disability (e.g., Turk & Melzack, 2011), since
intensity and disability tend to display only moderate correlations with each other (Schmidt et al.,
2010; Von Korff et al., 1992), and have demonstrated differential associations with healthrelated outcomes (e.g., healthcare utilization, presence of substance use disorders,
depression/anxiety; Bean et al., 2014; Day & Thorn, 2010; Häuser et al., 2014; McDermott et al.,
2018).
BZD Use in Chronic Pain: Prevalence and Impact
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Patterns of BZD use among individuals with chronic pain have generated substantial
concern among researchers and clinicians (Guina & Merrill, 2018; Pergolizzi & LeQuang, 2020),
with commensurate calls for additional research aimed at the explication of biopsychosocial
factors contributing to the maintenance and escalation of BZD use in pain populations.
Individuals with chronic pain represent a group at higher risk for BZD-related problems for
several reasons. First, treatment-seeking chronic pain samples may be 2-3 times as likely as
individuals in the general population to report BZD use (over 30% versus 5 - 15%; Agarwal &
Landon, 2019; Cunningham et al., 2017b; King & Strain, 1990; Nielsen et al., 2015) and to meet
criteria for BZD-related substance use disorder (e.g., Liebschutz et al., 2010). Among chronic
pain samples, greater pain intensity has been associated with a greater likelihood of endorsing
past-year (Torrance et al., 2018), past-month (Nielsen et al., 2015), and current BZD use
(Cunningham et al., 2017b), as well as misuse (Anagnostopoulos et al., 2018). Second, although
BZDs continue to be prescribed in the context of pain management (Agarwal & Landon, 2019;
Kim et al., 2018; Larochelle et al., 2015) following early work recommending BZDs to treat
affective components of pain (e.g., Dellemijn & Fields, 1994), evidence regarding BZD efficacy
in the vast majority of pain conditions is lacking (Wright, 2020).
Third, approximately 40% of individuals prescribed opioid analgesics also use BZDs
(Gudin et al., 2013), and such co-use is associated with increased risk of overdose and overdose
fatality via respiratory depression (Jeffery et al., 2019; Pergolizzi & LeQuang, 2020; Sun et al.,
2017). Indeed, risk of opioid-related overdose death may be ten-fold higher for patients also
prescribed a BZD (Dasgupta et al., 2016). Finally, it has been argued that management of
chronic pain and comorbid symptoms using BZDs may contribute to use without a plan or
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impetus for discontinuation (Pergolizzi & LeQuang, 2020), thus increasing the potential for
misuse.
Theoretical Perspectives Relevant to Pain-BZD Relations
An established reciprocal model suggests that pain and substance use interact in a
bidirectional manner, resulting in the maintenance and exacerbation of both conditions over time
(Ditre et al., 2019). Consistent with negative reinforcement (Baker et al., 2004) and selfmedication (Khantzian, 1997) paradigms that posit substance use is largely motivated by the
desire to ameliorate or escape aversive internal states, pain has been shown to be a potent
situational motivator of substance use (e.g., tobacco and alcohol; Ditre & Brandon, 2008; Ditre et
al., 2010; Moskal et al., 2018). Accordingly, substance use in the context of pain may be
reinforced via negative affect reduction, acute substance-related analgesia, and alleviation of
abstinence-induced hyperalgesia (Ditre et al., 2019).
Alleviation of negative affect also appears to play a central role in BZD use (Cox &
Klinger, 1988). Broadly, motivational models posit that decision-making is driven by
consideration of the net affective consequences of engaging in a given behavior, and motives
may be understood as the reasons for engaging in a given behavior (Ikard et al., 1969). Coping
motives (i.e., using a substance to reduce or cope with negative emotions) are among the most
commonly endorsed reasons for BZD use (Boyd et al., 2015; Fatséas et al., 2009; Kokkevi et al.,
2008; McCabe et al., 2009; McCabe & Cranford, 2012; McHugh et al., 2017; Vogel et al., 2013;
Votaw et al., 2019). Individuals also report using BZDs for somatic self-treatment motives, such
as alleviating symptoms of withdrawal from other substances (Messina et al., 2016; Vogel et al.,
2013). BZDs are commonly used in combination with opioids or opioid agonist medications
(e.g., methadone) to augment their effects, including pain relief (Dwyer, 2008; Hayashi et al.,
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2013; Lankenau et al., 2012; Mateu-Gelabert et al., 2017; Motta-Ochoa et al., 2017).
Importantly, many patients have reported receiving BZD prescriptions for chronic or postsurgical pain (Parr et al., 2006; Sirdifield et al., 2017) and for insomnia secondary to or
exacerbated by pain (Liebrenz et al., 2015; Sirdifield et al., 2017; Williams et al., 2016). Taken
together, this literature suggests that desire for pain alleviation is likely a salient motivator of
BZD use.
The Potential Role of Pain Catastrophizing in BZD-Pain Relations
To inform interventions for BZD use/dependence in the context of chronic pain, a critical
next step is identification of modifiable cognitive-affective factors that underlie pain-substance
use relations (i.e., transdiagnostic factors). One such factor is pain catastrophizing, understood as
a set of exaggerated, negative, cognitive-affective response styles or schemas related to pain
(e.g., ruminating on pain; Campbell et al., 2015; Edwards et al., 2011; Quartana et al., 2009).
Pain catastrophizing has been proposed as a key transdiagnostic factor underlying comorbid pain
and substance use (Ditre et al., 2019). Pain catastrophizing has been associated with greater
fear/worry about pain (Edwards et al., 2011; Quartana et al., 2009) and heightened anxiety
during pain induction (McHugh et al., 2020a) and, importantly, pain-related fear may increase
propensity to engage in escape/avoidance behaviors in response to pain, including substance use
(e.g., McCracken et al., 1992). Empirically, pain catastrophizing has been implicated in paindriven urge to use tobacco (Kosiba et al., 2018) and use of cannabis for pain-coping (Sterniczuk
& Whelan, 2016), and has been associated with greater risk of alcohol dependence (Ciccone et
al., 2010) and opioid misuse among individuals with chronic pain (e.g., Martel et al., 2013;
Morasco et al., 2013). Pain catastrophizing has also been shown to account for variance in
opioid/alcohol craving beyond that explained by pain severity (Kneeland et al., 2019), and in
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opioid misuse even after accounting for pain severity, anxiety, and depressive symptoms (Martel
et al., 2013). We are aware of only one prior study examining pain catastrophizing in relation to
BZD use, and results indicated a positive association between pain catastrophizing and
likelihood of BZD use (versus non-use) among 847 treatment-seeking pain patients
(Cunningham et al., 2017b).
The Present Study
In addressing a growing crisis regarding BZD use that has disproportionate impact on
chronic pain populations, critical next steps include elucidating the relationships of pain with
more granular, clinically relevant BZD use patterns (e.g., misuse, use frequency, and
dependence) as well as identification of potentially modifiable transdiagnostic factors underlying
pain and BZD use. The primary goal of the current study was to test whether pain intensity and
pain-related disability are associated with BZD misuse, severity of dependence, and past-month
BZD use frequency, among individuals who report a current BZD prescription and chronic
musculoskeletal pain. We hypothesized that greater pain intensity and pain-related disability
would be associated with greater past-month BZD use frequency, dependence symptoms, and
likelihood of BZD misuse. Given evidence that pain catastrophizing may play an important role
in pain-substance relations generally (e.g., Kneeland et al., 2019; Kosiba et al., 2018; Sterniczuk
& Whelan, 2016) and emerging evidence of correlations with BZD use (Cunningham et al.,
2017b), a secondary goal of this study was to examine the role of pain catastrophizing in BZD
use frequency/misuse/dependence, including as a potential moderator of hypothesized pain-BZD
relations. Specifically, we hypothesized that individuals scoring higher on a measure of pain
catastrophizing would display a) greater BZD use frequency, dependence, and likelihood of
misuse, and b) stronger relationships of pain with BZD use outcomes.
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Method
Participants and Recruitment
Participants were screened for the following inclusion criteria: ³ 18 years of age, current
prescription for one or more BZD medications (i.e., prescription sedatives and prescription
hypnotics; Substance Abuse and Mental Health Services Administration, 2018), current chronic
musculoskeletal pain, residence in the United States, and ability to read English (see Figure 1 for
participant flow chart).
Participants were recruited during March and April 2021 using the crowdsourcing
platform Amazon Mechanical Turk (mTurk), a growing source of health sciences and addictions
research data (Strickland & Stoops, 2019). First, a human intelligence task (HIT) was posted
describing survey content (“You will be asked to answer questions about your health and
behaviors.”), duration (~1-2 minute screening followed by ~20-35 minute survey), and
compensation ($3-$4). Consistent with prior work, access was limited to workers with U.S.
residence (Cunningham et al., 2017a; Huhn et al., 2018; Strickland et al., 2019b; Strickland &
Stoops, 2015). Next, prospective participants completed a two-part screening procedure designed
to mask the intent of the study and eligibility criteria, and thereby minimize deceptive
responding (Chandler & Shapiro, 2016; Strickland & Stoops, 2019). Consistent with best
practices (Boehnke et al., 2021; Dunn et al., 2016; Huhn et al., 2018; Strickland & Stoops, 2019),
a screening questionnaire was completed that contained items of interest for inclusion as well as
‘distractor questions’ unrelated to inclusion (Appendix E). Part I of the screener assessed age,
U.S. residence, ability to read English, and presence of chronic pain, and asked respondents to
endorse medications prescribed for them, with response options including “anxiety medications
or tranquilizers” and “sleeping medications” in addition to commonly prescribed medications not
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of interest for the study (e.g., blood pressure, thyroid, and cholesterol medications; Agency for
Healthcare Research and Quality, 2018). Provisionally eligible participants (i.e., those endorsing
age ³ 18 years, U.S. residence, English literacy, chronic pain, and prescription of an anxiety
medication/tranquilizer and/or sleeping medication) then advanced to the next page of the
screener.
Part II of the screener (Appendix E) was designed to verify the musculoskeletal nature of
chronic pain and receipt of a BZD anxiolytic and/or hypnotic. Participants were asked to report
their primary location of chronic pain, and those marking “fibromyalgia and/or widespread pain”
were excluded, given that differential processes are thought to underlie centralized versus
localized musculoskeletal pain (e.g., Arendt-Nielsen et al., 2011). Participants were asked to
endorse any medications currently prescribed to them from a list of BZD medications, as
assessed by NSDUH 2018. In order to minimize response bias, response options also included
non-BZD anxiolytics and hypnotics (e.g., eszopiclone, cyclobenzaprine), “None of the above,”
and “Not Sure/Don’t Know.”
Eligible participants then completed a brief (~25-minute) survey. All participants who
completed the full survey were compensated regardless of subsequent data exclusions.
Consistent with prior work (Beymer et al., 2018; Chandler & Shapiro, 2016; LaRowe et al.,
2021; Ruchensky et al., 2018; Strickland et al., 2019a; Strickland & Stoops, 2015, 2017) and an
estimated survey completion time of 25 minutes, survey respondents were compensated $3.004.001.
Online Survey

1

The first 55 participants were compensated $3 and compensation was raised to $4 for the remaining participants due to concerns
about recruitment feasibility.
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Additional measures were taken to address two key challenges of crowdsourced data:
insufficient effort responding (IER) and deceptive responding. IER may be defined as a response
set in which a participant completes survey measures with “low or little motivation to comply
with the survey instructions, correctly interpret item content, and provide accurate responses”
(Huang et al., 2012). Deceptive or disingenuous responding may involve endorsing behaviors in
order to qualify for a study one may not otherwise qualify for (e.g., by exaggerating current or
past substance use; Strickland & Stoops, 2019). Given that crowdsourced data precludes
biological verification of substance use, efforts to minimize disingenuous responding are critical
for use of crowdsourced data in addiction sciences (Black et al., 2019; Strickland & Stoops,
2019).
Incentives for deceptive responding result when participants can discern the purpose of a
study and the items or responses upon which inclusion (and thus, payment) is contingent.
Accumulating evidence suggests that deceptive responding is more likely when eligibility
criteria are known to participants (e.g., Chandler & Paolacci, 2017; Hydock, 2018; Sharpe
Wessling et al., 2017). For example, one study found that 89% of participants misrepresented
themselves when inclusion criteria were known, while under 5% did so when inclusion criteria
were hidden (Sharpe Wessling et al., 2017). Thus, best practices for minimizing disingenuous
responding include masking of inclusion criteria. Screening should be conducted as
unobtrusively as possible, for example by posting HITs that conceal the population being
sampled (e.g., Dunn et al., 2016; Wiens & Walker, 2015) and by utilizing a separate screening
questionnaire that masks actual eligibility requirements (Chandler & Shapiro, 2016; Hydock,
2018; Sharpe Wessling et al., 2017; Strickland & Stoops, 2019). Screening questionnaires
designed to conceal inclusion criteria often utilize additional questions unrelated to study
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eligibility criteria, such as dietary and sleep habits (Boehnke et al., 2021; Dunn et al., 2016;
Strickland et al., 2019b; Strickland & Stoops, 2019; Victor et al., 2020). Screening items for the
present study are provided in Appendix E.
Inconsistency methods provide another check on data quality post-survey completion. For
example, it is recommended to repeat select measures at two separate points during the survey
(e.g., screener and main survey) and exclude data from participants who respond inconsistently,
minimizing inattentive or disingenuous responding (Chandler & Shapiro, 2016; Strickland &
Stoops, 2019). Consistent with prior work (e.g., Strickland & Stoops, 2018; Victor et al., 2020),
repeated sets in the present survey included demographic (i.e., marital status) and substance use
items (i.e., past-year cigarette use). Data of respondents answering either of the two items
inconsistently were excluded.
Improbability methods provided a final check on disingenuous and/or careless
responding. Substance use crowdsourcing methodology papers have recommended exclusion of
participants who endorse recent use of a number of substances that is considered biologically
implausible (e.g., past-year non-medical use of > 35 substances; Black et al., 2019). While coprescription of 2 or more BZDs is relatively common (e.g., nearly 15% in a pain treatment
sample; Mikel et al., 2012; Pandraud-Riguet et al., 2017), participants in the present sample
reported up to 8 BZD prescriptions (i.e., selecting every answer choice). The modal number was
1 prescription and median was 2. Based on visual inspection of the distribution and distance from
the median, four was considered the maximum number not likely to indicate disingenuous
responding, and participants endorsing > 4 BZD prescriptions were excluded from analyses.
Measures
Sociodemographic Characteristics
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Participants were asked to report a range of sociodemographic characteristics, including
age, racial and ethnic identities, marital status, educational attainment, and household income.
Consistent with recent guidance for social sciences and psychology research (Cameron &
Stinson, 2019; Hughes et al., 2016; Puckett et al., 2020; Smith et al., 2019), sex was assessed
with the item: “What sex were you assigned at birth?” (Female, Male, Intersex), and gender
identity was separately assessed. Given previously observed associations with both BZD use
(versus non-use; e.g., Cunningham et al., 2017b; Maust et al., 2019; Olfson et al., 2015) and pain
(e.g., Fillingim et al., 2009; Mogil, 2012), age and sex were identified as a priori covariates for
all analyses.
BZD Prescription
Participants were asked to indicate which type(s) of BZD they were currently prescribed
by selecting from among the BZDs assessed in the National Survey on Drug Use and Health,
(Substance Abuse and Mental Health Services Administration, 2018), including both generic and
brand name examples: alprazolam products (Xanax, Xanax XR, Alprazolam, Extended-Release
Alprazolam), lorazepam products (Ativan, Lorazepam), clonazepam products (Klonopin,
Clonazepam), diazepam products (Valium, Diazepam), flurazepam (also known as Dalmane),
temazepam products (Restoril, Temazepam), triazolam products (Halcion, Triazolam), estazolam
products (Prosom), other benzodiazepine tranquilizers or sedatives.
For participants endorsing multiple BZD prescriptions, the primary BZD was defined as
that for which the participant’s maximum number of past-month days of use was indicated. In
other words, primary BZD indicated the participant’s most frequently used medication in the past
month. Past-month use frequency was calculated as the number of days of use reported by a
given participant for his/her primary BZD.
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BZD Dependence
The Severity of Dependence Scale (SDS) is a 5-item measure that has been validated as a
tool for assessing BZD dependence (Brett & Murnion, 2015; de las Cuevas et al., 2000). Items
assess: the extent to which individuals feel their BZD use is out of control, worry about the
prospect of missing a dose, worry about their BZD use, wish they could cease BZD use; and how
difficult they feel it would be to stop or go without BZDs. Items are rated on a 4-point scale (e.g.,
0 ‘never/almost never’ to 4 ‘always/almost always’) and summed to produce a total score (range:
0 to 15), with higher total scores reflecting greater severity of BZD dependence symptoms (i.e.,
‘dependence severity’). In a sample of 100 individuals reporting BZD use for at least 3 months
(de las Cuevas et al., 2000), the mean SDS score was 6.4 (SD = 3.8). The SDS has demonstrated
diagnostic utility for BZD dependence and use disorders. For example, the SDS has shown
sensitivity of 98% and specificity of 94% relative to DSM-IV diagnostic criteria for BZD
dependence (using a cutoff score of 6; de las Cuevas et al., 2000) and SDS scores have displayed
moderate, positive correlations with DSM-IV criteria for BZD substance dependence (r = 0.65;
Cheng et al., 2019). The SDS demonstrated acceptable internal consistency in the present sample
(Cronbach’s α = .774).
BZD Misuse
Past-12-month BZD misuse was assessed in a manner consistent with current NSDUH
definitions, i.e., misuse constitutes a) use without own prescription, b) use in greater amounts,
more often, or over a longer period than prescribed, and/or c) use in another way not as directed
by a physician (Substance Abuse and Mental Health Services Administration, 2018). Participants
were asked to indicate any of the above behaviors that applied to their past-12-month use of
BZDs. Consistent with prior literature examining misuse as a binary outcome (e.g., Day &
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Rosenthal, 2019; Nicholson & Ford, 2018), participants who endorsered one or more forms of
misuse were considered positive for BZD misuse.
BZD Use Frequency
Consistent with previous research, frequency of use was indicated by the self-reported
number of days using BZDs over the past month (e.g., Stein et al., 2016). Past-month days of use
has reliably been used to index current BZD use frequency (e.g., McHugh et al., 2017; Stein et
al., 2016) and identify individuals with current heavier current BZD use for clinical purposes
(e.g., informing treatment of concurrent opioid use problems; Stein et al., 2016).
Pain Locations
Participants were asked to mark all locations at which they experienced pain during the
past 3 months from among: back, head, face, neck, shoulders, arms, hands, chest, breast,
stomach, abdomen, hips, legs, feet, fibromyalgia and/or widespread pain. Participants were then
asked to select the primary location from those endorsed.
Chronic Pain Intensity and Pain-Related Disability
The Graded Chronic Pain Scale (GCPS; Von Korff et al., 1992) is a widely used and
reliable measure designed to grade the severity of chronic pain, assessing both pain intensity and
pain-related disability (Von Korff, 2011). The characteristic pain intensity score (“pain
intensity”) represents the sum of three NRS items assessing current, past-3-month worst, and
past-3-month average pain intensity (0 ‘no pain’ to 10 ‘pain as bad as it could be’). Higher total
scores (range: 0 to 30) represent greater characteristic pain intensity. The pain-related disability
score represents the sum of four NRS items assessing the extent to which pain has interfered with
daily functioning over the past 3 months (0 ‘no interference’ to 10 ‘unable to carry on any
activities’) across 3 domains (daily activities, social/family/recreational, and work) and one item

16
assessing number of days on which pain interfered with usual activities (0 ‘none’ to 10 = ‘76-90
days’). Higher total scores (range: 0 to 40) represent greater pain-related disability. GCPS pain
intensity and pain-related disability subscales demonstrated acceptable and good internal
consistency, respectively, in the present sample (Cronbach’s α = .718; α = .859).
Pain Catastrophizing Scale
The Pain Catastrophizing Scale (PCS; Sullivan et al., 1995) is a widely used 13-item
measure that has been validated in chronic pain populations (e.g., adult outpatient pain samples;
Osman et al., 2000; Sullivan et al., 1995). Respondents are asked the extent to which they
experience negative thoughts/emotions in response to pain, rated from 0 (‘not at all’) to 4 (‘all
the time’). Items are summed for a total score (range: 0 to 52) with higher total scores reflecting
greater tendency to catastrophize when in pain. The PCS is composed of 3 subscales: rumination
(e.g., “I keep thinking about how much it hurts”), magnification of pain-related threat (e.g., “I
wonder whether something serious might happen”), and feelings of helplessness (e.g., “There’s
nothing I can do to reduce the intensity of the pain”). This 3-factor structure has been supported
by confirmatory factor analyses (e.g., Osman et al., 2000). The PCS has demonstrated criterionrelated validity (i.e., differentiation of community and clinical pain samples); convergent validity
via moderate, positive correlations with negative affect and pain intensity and interference (e.g.,
Osman et al., 2000; Sullivan et al., 1995); and predictive validity in longitudinal studies (e.g.,
prediction of postoperative pain; Granot & Ferber, 2005; Petersen et al., 2020). In the present
sample, the PCS demonstrated excellent internal consistency (Cronbach’s α = .921).
Other Substance Use
Recent epidemiological studies indicate that BZD use is correlated with past-year
nicotine use and dependence; alcohol use and use disorders; and prescription opioid use, misuse,
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and use disorders (Blanco et al., 2018). Quantity and frequency of alcohol consumption were
assessed using the Modified Daily Drinking Questionnaire (DDQ-M; Collins et al., 1985;
Dimeff, 1999), which assesses typical weekly drinks per day over the past 3 months, allowing for
calculation of weekly averages. Problematic drinking patterns were assessed via the Alcohol Use
Disorders Identification Test (AUDIT; Bohn et al., 1995). Reliability and validity of the DDQ-M
(Carey et al., 2006) and AUDIT (e.g., Reinert & Allen, 2002) have been demonstrated in
previous work. The AUDIT demonstrated excellent internal consistency in the present sample
(Cronbach’s α = .908). Finally, participants were asked to report on use of prescription opioid
medications (Substance Abuse and Mental Health Services Administration, 2018) and complete
the Current Opioid Use Misuse Measure (COMM; Butler et al., 2007), a measure assessing pastmonth frequency of aberrant medication-related behaviors (e.g., taking pain medications
prescribed to someone else) that has been validated among those prescribed opioids in pain
treatment (Butler et al., 2010) and primary care settings (Meltzer et al., 2011).
Other Clinical Characteristics
Generalized anxiety symptoms were measured using the Generalized Anxiety Disorder –
7 item (GAD – 7; Spitzer et al., 2006), a measure with demonstrated reliability and convergent
validity in a heterogeneous psychiatric sample (Beard & Björgvinsson, 2014), primary care
samples (Spitzer et al., 2006), and the general population (Löwe et al., 2008). The 7 items
assessing symptom frequency are rated from 0 (‘not at all’) to 3 (‘nearly every day’) and
summed for a total score (range: 0 to 21). Scores above 10 are considered to indicate clinically
significant anxiety symptoms (Spitzer et al., 2006). The GAD-7 demonstrated good internal
consistency (Cronbach’s α = .82) in the present sample.
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The Insomnia Severity Index (ISI; Bastien et al., 2001) is a widely-used 7-item measure
of sleep disturbance that has demonstrated reliability and convergent validity in community and
clinical samples (e.g., Morin et al., 2011). Items are rated on 5-point Likert-type scales ranging
from 0 (‘not at all’) to 4 (‘extremely’), and higher total scores reflect more severe insomnia
(range: 0 to 28). Evaluation of two factors, “symptom severity” and “impact on functioning,” is
supported by results of confirmatory factor analysis (Otte et al., 2019) and differential
associations of each factor with relevant clinical correlates (e.g., depressive symptoms; Bazargan
et al., 2019). The Severity subscale (i.e., symptom severity) is the sum of 3 items measuring
severity of problems with sleep onset, sleep maintenance, and morning awakening, while the
Impact subscale (i.e., impact on functioning) is the sum of 3 items measuring distress,
interference with daily functioning, and noticeability of impairment. In the present sample, the
ISI total, Severity, and Impact scales each demonstrated acceptable internal consistency
(Cronbach’s α = .79, α = .71, α = .70, respectively).
Data Analytic Plan
All analyses were conducted using SPSS Version 26 (IBM Corp, 2019). First, all
variables were assessed for normality (skewness and kurtosis that fall within an acceptable range
-2 ≤ x ≤ 2; George & Mallery, 2011). Second, a series of bivariate correlations (continuous
variables) and point-biserial correlations (dichotomous variables) were run to test associations
between BZD use frequency, BZD dependence, BZD misuse, and participant characteristics
(Table 2). Variables that were associated with dependent variables (past-month BZD use
frequency, BZD dependence, BZD misuse) were retained as covariates in addition to covariates
selected a priori (age, sex; Cunningham et al., 2017b; Maust et al., 2019; Olfson et al., 2015).
The variance inflation factor (VIF) for each predictor was also assessed in order to identify
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issues of multicollinearity, which can decrease statistical power. Multicollinearity occurs when
two or more predictor variables are highly correlated. The VIF is commonly used to quantify a
given predictor’s inflation of the variance in the regression coefficient, and a VIF ³ 10 indicates
issues with multicollinearity (Myers, 1990).
Each linear regression model was assessed for model assumptions. Linearity of predictoroutcome relationships was indicated by scatterplots of each predictor-outcome pair. Zero mean,
equal variance, and independence of residuals were assessed via visual inspection of the
residuals versus fitted values plot, and independence of residuals was confirmed via DurbinWatson statistics falling within the acceptable range (1 ≤ x ≤ 3; Durbin & Watson, 1951).
Normality of residuals was assessed using residuals histograms. Models met all assumptions.
The logistic regression model (predicting misuse) was assessed for model assumptions.
The dependent variable, misuse, was dichotomous with mutually exclusive and exhaustive
categories (yes/no). Linearity of the relationship between predictors and log-odds of the outcome
was assessed using the Box-Tidwell procedure (Box & Tidwell, 1962). Linearity assumptions
were met for all predictors except pain intensity, for which the Box-Tidwell test suggested a nonlinear relationship. However, logistic regression models are considered robust to this violation of
linearity at sample sizes above ~250 (e.g., Bergtold et al., 2011).
Next, separate hierarchical linear regression models were conducted to test associations
between pain intensity and disability, and BZD dependence severity and past-month use
frequency. Covariates were entered in the first step of each model and pain intensity or disability
in the second. Relative contributions of pain intensity and disability to observed variance in
outcome variables were assessed by examining change in R-squared statistic (ΔR2) at the second
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step of each model. A hierarchical logistic regression model was conducted to test associations
between pain intensity and disability and likelihood of endorsing any past-year BZD misuse.
We then examined the interaction between pain intensity or disability and pain
catastrophizing by including an interaction term (pain intensity or disability x pain
catastrophizing) in each model. The order of variables entered in each model were as follows:
step 1 (covariates); step 2 (pain intensity or disability, pain catastrophizing); step 3 (pain
intensity or disability × pain catastrophizing interaction). In the case of significant interaction
terms, we further evaluated interactions using the PROCESS Macro for SPSS (Hayes, 2017) by
testing the conditional effects of pain intensity or disability at each of three levels of the
moderator (i.e., pain catastrophizing). Consistent with recommendations, associations were
probed at the 16th, 50th, and 84th percentiles of PCS Total scores (Hayes, 2017). In the case of
non-significant interactions, Step 2 of the model was examined.
Results
Data Quality
Figure 1 summarizes participant flow through screening procedures and reasons for
which data were excluded from analysis. A total of 2,379 individuals were screened in Qualtrics,
of whom N = 390 were eligible and chose to participate. Data were excluded from analysis for
any participant who failed inconsistency and/or attention checks (N = 65), did not complete
measures used as covariates (N = 8), or endorsed a number of current BZD prescriptions
considered likely to indicate disingenuous or inattentive responding (i.e., ≥ 5 prescriptions; N =
37).
Among the remaining N = 306 participants included in analyses, there was perfect
correspondence between “inconsistency check” items assessed at both the beginning and end of
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the survey (i.e., marital status, past-year cigarette use). Correlations in the expected direction
were observed between BZD dependence score and hazardous alcohol use patterns (AUDIT total
score; r = .714) and opioid misuse behaviors (COMM total score; r = .695), consistent with
previously observed associations of BZD dependence with alcohol/opioid misuse and
dependence (e.g., Gudin et al., 2013; Jeffery et al., 2019; McHugh et al., 2020b). As would be
expected based on prior literature (e.g., Herrero Babiloni et al., 2020; Lawton & Simpson, 2009;
Spitzer et al., 2006), pain intensity was moderately, positively correlated with hazardous alcohol
use patterns (AUDIT total score; r = .482), generalized anxiety symptoms (GAD - 7 total score; r
= .417), and insomnia symptoms (ISI total score; r = .538).
Participant Characteristics
A total of 390 individuals completed the survey. Following application of data quality
checks described above (Online Survey), the final sample included 306 adults (38.9% female;
Mage = 38.7, SD = 11.1) who reported at least one current BZD prescription. The sample was
predominantly white (68.6%) and 2.6% reported Hispanic ethnicity. Over 60% of participants
reported earning at least $50,000 in annual household income. Sociodemographic and clinical
characteristics are summarized in Table 1.
In terms of pain, participants reported a mean of 77.6 pain days in the past 6 months (SD
= 56.7). Characteristic pain intensity scores ranged from 5 to 30 (M = 21.1, SD = 4.7) and painrelated disability scores ranged from 3 to 40 (M = 25.5, SD = 6.9). Approximately 90% of the
sample was classified in GCPS Pain Grades III or IV, indicating moderate to severe pain
interference. The most commonly endorsed primary pain locations included back (36.3%) and
head/neck (30.7%). Mean PCS score was 30.7 (SD = 10.5) indicating high pain catastrophizing
on average (Sullivan et al., 1995).
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In terms of BZD use, 43.1% of participants reported that first BZD prescription use was
longer than 12 months ago. The most commonly reported primary BZDs (i.e., those with highest
past-month days of use) were alprazolam (32%), lorazepam (17%), clonazepam (14%), and
diazepam (13%). The mean SDS score of 7.7 (SD = 3.3) suggests moderate severity of BZD
dependence. Mean number of days using BZDs was 14.2 (SD = 10.0) in the past month.
Participants were asked to indicate all reasons for which a BZD had been prescribed to them, and
the most commonly endorsed included anxiety (46%), pain (45%), insomnia (23%), and
neurologic conditions (11%). Participants also reported all conditions/symptoms for which they
seek relief by taking BZDs, and the most commonly endorsed included pain (56%), anxiety
(48%), depression (44%), insomnia/sleep problems (27%), and neurological conditions (11%).
For those endorsing multiple conditions/symptoms, the most common combinations were
depression-pain (26%), anxiety-depression (23%), anxiety-pain (18%), insomnia-pain (14%),
and anxiety-insomnia (13%). Over one-third of the sample reported pain as the main
condition/symptom that they seek to relieve by taking BZDs.
Bivariate Correlations
All bivariate correlations are presented in Table 2. Significant associations were observed
for past-month days of use with race (white vs. non-white; r = -.185, p = .001) and education (r =
-.162, p =.005); for BZD dependence severity with race (r = .165, p = .004) and education (r =
.310, p < .001); and for BZD misuse with sex (r = .161, p = .005), race (r = .122, p = .033), and
education (r = .334, p = < .001). Therefore, race and education were retained as covariates in all
analyses. As expected, pain intensity was highly, positively correlated with pain-related
disability (r = .726, p < .001); and moderately, positively correlated with pain catastrophizing (r
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= .454, p < .001). Further, pain intensity was moderately, positively correlated with BZD
dependence severity (r = .543, p < .001).
Model Assumptions
Models predicting BZD use frequency/dependence severity and likelihood of BZD
misuse met assumptions for linear regression and logistic regression, respectively, as described
in the Data Analytic Plan. There was no indication of multicollinearity based on VIF for any
predictor variable: pain intensity (VIFs < 1.35), pain catastrophizing (VIFs < 1.35), sex (VIFs <
1.05), age (VIFs < 1.15), and education (VIFs < 1.10). Results of hierarchical linear regression
and logistic regression models are presented below and in Tables 3-5. Results of pain
catastrophizing moderation models can be found in Tables 6-8.
Pain Intensity and Disability and BZD Dependence, Misuse, and Use Frequency
Pain intensity was positively associated with severity of BZD dependence (Table 3;
F[1,299] = 114.863, p < .001, ∆R2 = .245) and with past-month use frequency (Table 5; F[1,299]
= 5.955, p = .015, ∆R2 = .018). Pain intensity accounted for 24.5% and 1.8% of unique variance
in dependence severity and past-month use frequency, respectively, after accounting for all other
variables in the models. Pain-related disability was significantly positively associated with
severity of BZD dependence (Table 3; F[1,299] = 127.156, p < .001, ∆R2 = .264) and accounted
for 26.4% of unique variance in BZD dependence score, after accounting for all other variables
in the model. Pain-related disability was not associated with past-month use frequency (Table 5;
F[1,299] = 1.710, p = .192, ∆R2 = .005).
Greater pain intensity was associated with greater likelihood of endorsing past-year BZD
misuse (Table 4; adjusted odds ratio [AOR] = 1.204, 95% confidence interval [CI]: 1.107-1.309,
p < .001). Specifically, for every one-point increase in pain intensity score, participants were 1.2
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times as likely to endorse past-year BZD misuse. Greater pain-related disability was associated
with a similar greater likelihood of past-year BZD misuse (Table 4; AOR = 1.147, 95% CI:
1.085-1.212, p < .001). Post hoc analyses of misuse subtypes further indicated that pain intensity
was positively associated with use without own prescription (AOR = 1.125, 95% CI: 1.057 –
1.197, p < .001) and use in greater amounts than prescribed (AOR = 1.078, 95% CI: 1.022 –
1.137, p = .006). Pain-related disability was similarly associated with use without own
prescription (AOR = 1.102, 95% CI: 1.054-1.152, p < .001), use in greater
amounts than prescribed (AOR = 1.061, 95% CI: 1.024-1.100, p = .001), and use over longer
periods of time than prescribed (AOR = 1.042, 95% CI: 1.001-1.084, p = .043).
Pain Catastrophizing and BZD Dependence, Misuse, and Use Frequency
In linear regression models assessing pain intensity x pain catastrophizing interaction
terms (Table 6), pain catastrophizing was positively associated with dependence severity (Step 2;
β = .506, p < .001) at Step 2 of the model. In contrast, pain catastrophizing was negatively
associated with past-month BZD use frequency (Step 2: β = -.151, p = .016) at Step 2 of the
model. Tests examining pain catastrophizing as a moderator of pain intensity-BZD relationships
were non-significant (Step 3: ps > .14).
Similarly, in linear regression models assessing pain-related disability x pain
catastrophizing interaction terms (Table 7), pain catastrophizing was positively associated with
BZD dependence severity (Step 2: β = .491, p < .001) at Step 2 of the model. In contrast, pain
catastrophizing was not significantly associated with past-month BZD use frequency (Step 2: β =
-.128, p = .050) at Step 2 of the model. Tests examining pain catastrophizing as a moderator of
pain-related disability-BZD relationships were non-significant (Step 3: ps > .91).
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Finally, in logistic regression models assessing pain intensity or disability x pain
catastrophizing interaction terms (Table 8), pain catastrophizing was positively associated with
likelihood of endorsing BZD misuse at Step 2 of both the pain intensity model (Step 2: AOR =
1.122, 95% CI: 1.072-1.174, p < .001) and pain-related disability model (Step 2: AOR = 1.115,
95% CI: 1.065-1.168, p < .001). Specifically, for every one-point increase in pain catastrophizing
score, participants were approximately 1.1 times as likely to endorse past-year BZD misuse after
accounting for either pain intensity or pain-related disability. Tests examining pain
catastrophizing as a moderator were non-significant (Step 3: ps > .09).
Discussion
The current study is the first to examine pain intensity, pain-related disability, and pain
catastrophizing in relation to clinically relevant patterns of BZD use (i.e., dependence, misuse) in
a chronic pain population. Among a sample of adults with chronic musculoskeletal pain
reporting current prescriptions of BZD anxiolytics and/or hypnotics, both chronic pain intensity
and disability were positively associated with severity of BZD dependence symptoms and
likelihood of BZD misuse, consistent with hypotheses. Pain intensity and pain-related disability
accounted for 24.5% and 25.9% of unique variance in BZD dependence, respectively, after
controlling for relevant sociodemographic factors. Individuals with greater pain intensity also
reported greater past-month days of BZD use, an index of current heaviness of BZD use.
Additionally, pain catastrophizing accounted for variance in BZD use outcomes above and
beyond that attributable to pain intensity or disability. Notably, over half of all participants
endorsed pain as a symptom for which they seek relief by taking BZDs. Overall, these initial
findings suggest that individuals with chronic pain who report greater pain intensity or painrelated disability also tend to score higher on indices of clinically relevant BZD use outcomes
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(dependence, misuse). Further, results implicate pain catastrophizing in BZD use among
individuals with chronic pain.
The present findings of positive covariation of pain intensity and pain-related disability
with BZD misuse and dependence build upon a limited literature on pain-BZD relations. Prior
studies have found that greater pain intensity is associated with greater likelihood of past-month
and current BZD use (Cunningham et al., 2017b; Nielsen et al., 2015), but higher-risk use
patterns have been underexamined. Moreover, these findings are largely consistent with an
established reciprocal model of pain and substance use (Ditre et al., 2019), which posits that pain
and substance use interact in the manner of a positive feedback loop and exacerbate both
conditions over time through multiple mechanisms (e.g., dysregulation of overlapping neural
reward circuitry; Elman & Borsook, 2016; Simons et al., 2014). Pain is a salient motivator of
substance use (e.g., tobacco and alcohol; Ditre & Brandon, 2008; Ditre et al., 2010; Moskal et
al., 2018), and substance use in the context of pain may be reinforced via negative affect
reduction and pain alleviation (Ditre et al., 2019). Moreover, research on BZD motives
specifically has shown that negative affect alleviation and enhancing analgesic effects of other
substances (e.g., opioids) are primary motives that individuals report for BZD use (Boyd et al.,
2015; Hayashi et al., 2013; McCabe & Cranford, 2012; Vogel et al., 2013). Taken together, this
prior literature suggests that pain may be a salient motivator of BZD use. Future experimental
and longitudinal research is needed to test whether pain may motivate BZD use and elucidate
mechanisms in pain-BZD relations.
Pain catastrophizing scores demonstrated positive associations with BZD dependence
but, contrary to expectations, negative associations of small magnitude with past-month days of
BZD use. These findings were unexpected given prior research demonstrating positive relations
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between pain catastrophizing and likelihood of BZD use (versus non-use) among pain patients
(Cunningham et al., 2017b). Several observations may help to explain this discrepancy. First, it
is possible that different factors may explain variation in use frequency among a sample all
prescribed BZDs, as compared with likelihood of BZD prescription in a sample not selected for
BZD use. Second, the present findings are broadly consistent with reports of alcohol use among
a chronic pain sample (Nieto et al., 2021). Nieto and colleagues found that pain intensity and
pain catastrophizing were both positively associated with alcohol dependence and alcohol
craving, while only pain intensity, and not pain catastrophizing, was associated with selfreported alcohol consumption (drinks/day). Thus, pain catastrophizing may be most relevant to
outcomes that are closely connected with dependence symptoms (Kneeland et al., 2019; Nieto et
al., 2021).
The current results should be interpreted in the context of several limitations. First, these
analyses were cross-sectional, thus precluding causal interpretations and inferences regarding
directionality. Additional work is needed to elucidate temporal relationships between pain and
BZD use, and could draw on methods such as intensive longitudinal designs to examine temporal
correspondence between pain experience and BZD self-administration in real-world settings
(e.g., Bolger & Laurenceau, 2013). Second, these data were collected via online survey and there
was no verification of self-reported medication use, and thus it is possible that participants
misrepresented or exaggerated behaviors. Of note, deceptive responding has been shown to
decrease in the absence of financial incentives (i.e., when participants cannot tell which
responses will allow them access to the study; Sharpe Wessling et al., 2017), and the present
study utilized recommended screening methods to conceal inclusion criteria and minimize
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financial incentives (see Method). Future work may benefit from implementing additional checks
(e.g., factual knowledge checking; Chandler & Shapiro, 2016).
Third, it is important to consider issues of generalizability. Mechanical Turk workers
have demonstrated demographic differences from nationally representative samples (e.g., higher
average educational attainment; Berinsky et al., 2012; Paolacci & Chandler, 2014; Walters et al.,
2018), as well as higher prevalence of tobacco cigarette use (22-25%; Johnson et al., 2015; Reese
& Veilleux, 2016) and lifetime use of illicit substances (e.g., cocaine, heroin, and
methamphetamine; Strickland & Stoops, 2019). Future work is needed to generalize findings
across samples recruited via a variety of sampling methods. Finally, given health risks associated
with BZD-opioid (e.g., Jeffery et al., 2019; Kandel et al., 2017) and BZD-alcohol co-use (e.g.,
Jones et al., 2012; Ogbu et al., 2015) and prevalence of both opioid and alcohol use among
individuals with chronic pain (e.g., Brennan et al., 2005; Daubresse et al., 2013; Larson et al.,
2007), these co-use types are impactful and warrant attention further research among individuals
using BZDs in the context of chronic pain.
In summary, this is the first study to examine pain intensity, pain-related disability, and
pain catastrophizing in relation to clinically relevant BZD use outcomes, including dependence
and misuse, among individuals with chronic pain. The present study builds upon limited prior
literature examining BZD use in chronic pain populations, providing initial evidence of positive
covariation of several clinically relevant pain characteristics with heavier, more problematic
patterns of BZD use. These preliminary findings implicate pain and pain-related cognitiveaffective processes in higher-risk BZD use, and suggest that pain relief is a common, yet
underrecognized, self-reported motivation for taking BZDs. Limited prior research has examined
the role of pain in relation to problematic patterns of BZD use, despite growing concern related
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to heavy BZD use, misuse, and dependence in chronic pain populations. Future research should
investigate mechanisms in pain-BZD relationships (e.g., negative reinforcement via
pain/negative affect reduction, allostatic load processes), as well as contributions of pain to
harmful BZD-alcohol and BZD-opioid co-use behaviors.
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Table 1
Participant Characteristics
n (%)
Gender
Female
Ethnicity
Hispanic/Latino
Race
American Indian/Alaska Native
Asian
Black or African American
Middle Eastern or North African
White
Other
Marital Status
Single
Married
Divorced/Separated/Widowed
Education
High school graduate or GED
Some college
Technical/Associates degree
4-year college degree
Some school beyond college
Professional degree (e.g., JD, MD)
Household Income
<$10,000
$10,000-24,999
$25,000-49,999
$50,000-$74,999
³$75,000
Anxiety Symptoms a
None to mild
Moderate to severe
Hazardous or Harmful Drinking b
Past-6-Month Cannabis Use
Past-Year Cigarette Use

119(38.9)
8(2.6)
8(2.6)
9(2.9)
75(24.5)
2(0.7)
210(68.6)
2(0.7)
38(12.4)
259(84.6)
9(2.9)
7(2.3)
23(7.5)
14(4.6)
174(56.9)
11(3.6)
77(25.2)
7(2.5)
25(8.2)
89(29.1)
108(35.3)
77(25.2)
80(26.1)
226(73.9)
242(79.1)
136(44.4)
270(88.2)
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M (SD)
38.7(11.1)
1.7(1.9)
17.0 (5.6)
16.9(4.8)
7.2(2.5)
7.5(2.3)

Range
18 - 77
0 - 12
0 - 28
1 - 27
0 - 12
0 - 12

Age
Mean Daily Drinks c
Opioid Misuse Behaviors d
ISI e total score
ISI Severity score
ISI Impact score
N = 306 unless noted otherwise.
a
General Anxiety Disorders – 7
b
Alcohol Use Disorders Identification Test (AUDIT) Score ³ 8
c
Modified Daily Drinks Questionnaire (DDQ-M); N = 270.
d
Current Opioid Misuse Measure (COMM); N = 268.
e
Insomnia Severity Index
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Table 2
Bivariate and Point-Biserial Correlations Between Sociodemographic, Pain Characteristics,
Primary Predictor, and Primary Outcome Variables
Variable
1 2
3
4
5
6
7
8
9
10
11
12
1 Sex
- -.08 .06 .06 .03
-.10 -.05
.03
.10
-.05
.06 .16**
2 Age
3 Race

a

-.01 -.05
-

4 Education
5 Income

.02

.11

.06

-.04

.01

-.06

.08

.12* -.19** .17** .12*

.12*

-.02

.07

.12*

-

.23**

.01

.16** .16** .16** -.16** .31** .33**

-

-.17**

.09

.10

-.04

-.10

.06

.01

-

.06

.11

-.01

-.07

.09

.06

6 Marital status
7 Pain intensity

-

b

8 Pain-related
disability c
9 Pain
catastrophizing

.73** .45**
-

d

10 Past-month
use frequency
11 Dependence
severity e
12 Misuse f
a

.26** .18**

.08

.54** .29**

.51**

.03

.57** .35**

-

-.11

.67** .45**

-

-.05

-.12*

-

.57**
-

b

Note. N = 306. White versus non-white; Graded Chronic Pain Scale – Characteristic Pain
Intensity; c Graded Chronic Pain Scale – Disability; d Pain Catastrophizing Scale total score; e
Severity of Dependence Scale total score; f No misuse versus any misuse in past year; * p < .05;
** p < .01.
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Table 3
Pain Intensity and Disability on BZD Dependence (Severity of Dependence Scale Score)
Severity of Dependence Scale Score
Variable
β
t
p
Sex
.063
1.356
.176
Age
-.064
-1.361
.175
Race
.073
1.554
.121
Education
.212
4.480
< .001**
Pain intensity a
.515
10.717
< .001**
2
R
.360
ΔR2
.245
2
F for ΔR
114.863**
β
t
p
Sex
.021
.460
.646
Age
-.030
-.652
.515
Race
.094
2.052
.041*
Education
.210
4.516
< .001**
Pain-Related Disability b
.525
11.276
< .001**
R2
.378
ΔR2
.264
2
F for ΔR
127.156**
Note: N = 306. Results shown are from the second step of each linear regression model; β =
standardized beta weights; Sex: Reference group = female; Race: Reference group = white; a
Graded Chronic Pain Scale – Characteristic Pain Intensity; b Graded Chronic Pain Scale –
Disability; * p < .05, ** p < .01
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Table 4
Logistic Regression: Pain Intensity and Disability on Likelihood of BZD Misuse
Variable
B
SE
AOR
95% CI
p
Sex
-1.082
.383
.339
.160 - .718 .005**
Age
-.028
.016
.973
.943-.1.004
.083
Race
-.484
.453
.616
.254-1.497
.285
Education
.753
.170
2.123
1.522-2.961 < .001**
Pain intensity a
.185
.043
1.204
1.107-1.309 < .001**
Sex
-.920
.385
.399
.188-.848
.017*
Age
-.020
.017
.980
.948-1.013
.224
Race
-.454
.468
.635
.254-1.588
.332
Education
.778
.176
2.178
1.543-3.074 < .001**
Pain-Related Disability b
.137
.028
1.147
1.085-1.212 < .001**
Note: N = 306. Results shown are from the second step of each logistic regression model; AOR =
adjusted odds ratio; Sex: Reference group = female; Race: Reference group = white; a Graded
Chronic Pain Scale – Characteristic Pain Intensity; b Graded Chronic Pain Scale – Disability; * p
< .05, ** p < .01.
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Table 5
Pain Intensity and Disability on Past-Month and BZD Use Frequency
Past-Month Use Frequency
β
t
p
-.031
-.559
.577
-.077
-1.360
.175
-.181
-3.220
.001**
-.165
-2.902
.004**
.141
2.440
.015*
.076
.018
5.955*
β
t
p
Sex
-.041
-.725
.469
Age
-.060
-1.059
.291
Race
-.171
-3.028
.003**
Education
-.154
-2.698
.007**
Pain-related disability b
.075
1.308
.192
R2
.063
ΔR2
.005
F for ΔR2
1.710
Note: N = 306; Results shown are from the second step of each linear regression model; β =
standardized beta weights; Sex: Reference group = female; Race: Reference group = white; a
Graded Chronic Pain Scale—Characteristic Pain Intensity; b Graded Chronic Pain Scale—PainRelated Disability; * p < .05, ** p < .01.
Variable
Sex
Age
Race
Education
Pain intensity a
R2
ΔR2
F for ΔR2
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Table 6
Pain Intensity, Pain Catastrophizing, and BZD Dependence and Use Frequency
BZD Dependence Score
β
t
p
ΔR2
p for ΔR2
Step 1
.115
< .001**
Sex
.036
.660
.510
Age
.031
.563
.574
Race
.128
2.340
.020*
Education
.294
5.369 < .001**
Step 2
.442
< .001**
Pain Intensity a
.290
6.526 < .001**
Pain Catastrophizing b
.506
11.517 < .001**
Step 3
.001
.418
Pain Intensity * Pain
-.181
-.812
.418
Catastrophizing
Past-Month BZD Use Frequency
β
t
p
ΔR2
p for ΔR2
Step 1
.001*
.058
Sex
-.039
-.687
.493
Age
-.051
-.911
.363
Race
-.166
-2.946
.003*
Education
-.142
-2.519
.012*
Step 2
.036
.003*
a
Pain Intensity
.208
3.267
.001*
Pain Catastrophizing b
-.151
-2.411
.016*
Step 3
.007
.142
Pain Intensity * Pain
-.469
-1.471
.142
Catastrophizing
Note: N = 306. β = standardized beta weights; Sex: Reference group = female; Race: Reference
group = white; a Graded Chronic Pain Scale – Characteristic Pain Intensity; b Pain
Catastrophizing Scale total score; * p < .05; ** p < .001.
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Table 7
Pain-Related Disability, Pain Catastrophizing, and BZD Dependence and Use Frequency
BZD Dependence Score
β
t
p
ΔR2
p for ΔR2
Step 1
.115
< .001**
Sex
.036
.660
.510
Age
.031
.563
.574
Race
.128
2.340
.020*
Education
.294
5.369 < .001**
Step 2
.439
< .001**
Pain-Related Disability a
.287
6.354 < .001**
Pain Catastrophizing b
.491
10.840 < .001**
Step 3
.000
.912
Pain-Related Disability * Pain
-.020
-.111
.912
Catastrophizing
Past-Month BZD Use Frequency
β
t
p
ΔR2
p for ΔR2
Step 1
.001*
.058
Sex
-.039
-.687
.493
Age
-.051
-.911
.363
Race
-.166
-2.946
.003*
Education
-.142
-2.519
.012*
Step 2
.017
.063
a
Pain-Related Disability
.137
2.104
.036*
Pain Catastrophizing b
-.128
-1.967
.050
Step 3
.000
.931
Pain-Related Disability * Pain
.022
.087
.931
Catastrophizing
Note: N = 306. β = standardized beta weights; Sex: Reference group = female; Race: Reference
group = white; a Graded Chronic Pain Scale – Disability; b Pain Catastrophizing Scale total score;
* p < .05; ** p < .001.
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Table 8
Logistic Regression: Pain Intensity and Disability, Pain Catastrophizing, and Likelihood of BZD
Misuse
Variable
Step 1
Sex
Age
Race
Education
Step 2
Pain Intensity a
Pain Catastrophizing b
Step 3
Pain Intensity x Pain
Catastrophizing
Step 1
Sex
Age
Race
Education
Step 2
Pain-Related Disability c
Pain Catastrophizing b
Step 3
Pain-Related Disability x Pain
Catastrophizing

B

SE

AOR

95% CI

p

-.871
-.011
-.548
.864

.356
.015
.435
.168

.418
.989
.578
2.373

.208-.841
.015*
.960-1.019
.454
.246-1.356
.208
1.707-3.299 < .001**

.107
.115

.054
.023

1.113
1.122

1.002-1.237 .046*
1.072-1.174 < .001**

.008

.005

1.008

.999-1.017

-.871
-.011
-.548
.864

.356
.015
.435
.168

.418
.989
.578
2.373

.208-.841
.015*
.960-1.019
.454
.246-1.356
.208
1.707-3.299 < .001**

.078
.109

.033
.023

1.081
1.115

1.014-1.153 .017*
1.065-1.168 < .001**

.002

.003

1.002

.996-1.007

.093

.552

Note: N = 306. Results shown are from the second step of each logistic regression model; AOR =
adjusted odds ratio; Sex: Reference group = female; Race: Reference group = white; a Graded
Chronic Pain Scale – Characteristic Pain Intensity; b Pain Catastrophizing Scale total score; c
Graded Chronic Pain Scale – Disability; * p < .05, ** p < .01.
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Figure 1. Participant Flow and Data Exclusions
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Appendix A
Graded Chronic Pain Scale (GCPS)

1. On how many days in the last 180 days (6 months) have you had pain? _________ days

2. How would you rate your pain RIGHT NOW?

No
Pain
0

1

2

3

4

5

6

7

8

9

Pain as
bad as
could
be
10

9

Pain as
bad as
could
be
10

9

Pain as
bad as
could
be
10

3. In the last 3 months, how would you rate your WORST pain?

No
Pain
0

1

2

3

4

5

6

7

8

4. In the last 3 months, ON AVERAGE, how would you rate your pain?

No
Pain
0

1

2

3

4

5

6

7

8

5. In the last 3 months, how many days did pain keep you from doing DAILY ACTIVITIES
(work, school, homework)?
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None

1

2

3-4

5-6

7-19

11-15

16-24

25-60

61-75

76-90

6. In the last 3 months, how much has pain interfered with your DAILY ACTIVITIES?

No
Interference
0

1

2

3

4

5

6

7

8

9

Unable
to carry
on any
activities
10

7. In the last 3 months, how much has pain interfered with your RECREATIONAL, SOCIAL,
& FAMILY ACTIVITIES?

No
Interference
0

1

2

3

4

5

6

7

8

9

Unable
to carry
on any
activities
10

8. In the last 3 months, how much has pain interfered with your ABILITY TO WORK,
including housework?

No
Interference
0

1

2

3

4

5

6

7

8

9

Unable
to carry
on any
activities
10
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Appendix B
Benzodiazepine Types and Benzodiazepine Prescription Assessment

Are you currently prescribed one or more of the following?
Alprazolam products (Xanax, Xanax XR, Alprazolam, Extended-Release
Alprazolam)
Lorazepam products (Ativan, Lorazepam)
Clonazepam products (Klonopin, Clonazepam)
Diazepam products (Valium, Diazepam)
Flurazepam (also known as Dalmane)
Temazepam products (Restoril, Temazepam)
Triazolam products (Halcion, Triazolam)
Estazolam (Prosom)
Other benzodiazepine tranquilizers or sedative
Please enter the name of any other benzodiazepine sedative or tranquilizer that is prescribed to
you currently. ______________
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Appendix C
Severity of Dependence Scale (SDS)

Instructions: Consider your use of benzodiazepine sedatives/tranquilizers (such as
Xanax/alprazolam, Ativan/lorazepam, Valium/diazepam).
Over the last 3 MONTHS:
0

1

2

3

Never/

Sometimes

Often

Always/

Almost

Nearly

Never

Always

Did you think your use of
sedatives/tranquilizers was out of
control?
Did the prospect of missing a dose make
you anxious or worried?
Did you worry about your use of
sedatives/tranquilizers?
Did you wish you could stop?

How difficult would you find it to stop or go without your sedatives/tranquilizers?
0

1

2

3

Not Difficult

Quite Difficult

Very Difficult

Impossible
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Appendix D
Pain Catastrophizing Scale (PCS)
Instructions: We are interested in the types of thoughts and feelings that you have when you are
in pain. Listed below are thirteen statements describing different thoughts and feelings that may
be associated with pain. Using the following scale, please indicate the degree to which you have
these thoughts and feelings when you are experiencing pain.

When I’m in pain…

I worry all the time about whether
the pain will end.
I feel I can’t go on.
It’s terrible and I think it’s never
going to get any better.
It’s awful and I feel that it
overwhelms me.
I feel I can’t stand it anymore.
I become afraid that the pain will
get worse.

0

1

2

3

4

Not at all

To a

To a

To a

All the

slight

moderate

great

time

degree

degree

degree
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I keep thinking of other painful
events.
I anxiously want the pain to go
away.
I can’t seem to keep it out of my
mind.
I keep thinking about how much it
hurts.
I keep thinking about how badly I
want the pain to stop.
There’s nothing I can do to reduce
the intensity of the pain.
I wonder whether something
serious may happen.
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Appendix E

Screening Questions—Part I:
1. What is your age? ____ years

2. What is your country of residence? (a dropdown menu of all possible responses will be

provided)

3. Do you read English well?

___ Yes
___ No
4. Have you smoked a cigarette in the past year?

___ Yes
___ No
5. How many minutes of TV (including movies and online streaming) do you watch per

day? (dropdown of options from 0-1000 minutes, by 10s)

6. How many minutes of TV (including movies and online streaming) do you think the

average person who is your age watches per day? (dropdown of options from 0-1000
minutes, by 10s)

7. Would you say that your general health is:

a. Excellent
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b. Very Good
c. Good
d. Fair
e. Poor
f. Don’t Know/Not Sure

8. Do you currently suffer from any type of chronic pain, that is, pain that occurs constantly

or flares up frequently? Do not report aches and pain that are fleeting or minor.
___ Yes
___ No

9. Are you currently prescribed any of the following medications by your doctor or other

healthcare provider?
a. Thyroid medications (such as Levothyroxine)
b. Blood pressure medications (such as Prinivil and Zestril/lisinopril)
c. Cholesterol medications (such as Lipitor/atorvastatin)
d. Diabetes medications (such as metformin)
e. Heartburn medications (such as Prilosec/omeprazole)
f. Antidepressant medications (such as Prozac/fluoxetine, Zoloft/sertraline)
g. Anxiety medications or tranquilizers (Xanax/alprazolam, Ativan/lorazepam,
Klonopin/clonazepam, Valium/diazepam, Flexeril, Soma)
h. Sleeping medications (such as Dalmane/flurazepam, Restoril/temazepam,
Halcion/triazolam, Lunesta, Ambien)
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i. Not Sure/Don’t Know

10. What type of soda do you typically drink?

a. Regular
b. Diet
c. Both types
d. I do not drink soda
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Screening Questions—Part II

1. Are you currently prescribed one or more of the following?

__ Alprazolam products (Xanax, Xanax XR, Alprazolam, Extended-Release Alprazolam)
__ Lorazepam products (Ativan, Lorazepam)
__ Clonazepam products (Klonopin, Clonazepam)
__ Diazepam products (Valium, Diazepam)
__ Cyclobenzaprine (Flexeril)
__ Soma
__ Flurazepam (also known as Dalmane)
__ Temazepam products (Restoril, Temazepam)
__ Triazolam products (Halcion, Triazolam)
__ Estazolam (Prosom)
__ Eszopiclone products (Lunesta)
__ Zolpidem products (Ambien, Ambien CR, Zolpidem)
__ Barbiturates (Butisol, Seconal, Phenobarbital)
__ Other benzodiazepine tranquilizers or sedative
__ None of the above
__ Not Sure/Don’t Know
11b. Please enter the name of any other benzodiazepine sedative or tranquilizer that is
prescribed to you currently. ___________________________
2. Please mark all locations at which you experienced pain during the past 3 months. Then,

please select your primary pain location, that is, the location that hurts the most.
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___ Back

___ Arms

___ Abdomen

___ Head

___ Hands

___ Hips

___ Face

___ Chest

___ Legs

___ Neck

___ Breast

___ Feet

___ Shoulders

___ Stomach

___ Fibromyalgia/widespread
pain

3. To monitor quality, please respond with a two for this item.

__ 1
__ 2
__ 3
__ 4
__ 5

51
References
Agarwal, S. D., & Landon, B. E. (2019). Patterns in outpatient benzodiazepine prescribing in the
United States. JAMA Network Open, 2(1), e187399.
Agency for Healthcare Research and Quality. (2018). Medical Expenditure Panel Survey
(MEPS). https://www.ahrq.gov/data/meps.html
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), Fifth edition. Arlington, VA: Author.
Anagnostopoulos, A., Abraham, A. G., Genberg, B. L., Kirk, G. D., & Mehta, S. H. (2018).
Prescription drug use and misuse in a cohort of people who inject drugs (PWID) in
Baltimore. Addictive Behaviors, 81, 39-45.
Arendt-Nielsen, L., Fernández-de-Las-Peñas, C., & Graven-Nielsen, T. (2011). Basic aspects of
musculoskeletal pain: from acute to chronic pain. Journal of Manual and Manipulative
Therapy, 19(4), 186-193.
Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current
Opinion in Psychiatry, 18(3), 249-255.
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016). Increasing
benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013.
American journal of public health, 106(4), 686-688.
Badley, E. M., Rasooly, I., & Webster, G. K. (1994). Relative importance of musculoskeletal
disorders as a cause of chronic health problems, disability, and health care utilization:
findings from the 1990 Ontario Health Survey. Journal of Rheumatology, 21(3), 505-514.

52
Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E. (2014). The diagnosis of and
treatment recommendations for anxiety disorders. Deutsches Ärzteblatt International,
111(27-28), 473-480.
Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues
in Clinical Neuroscience, 19(2), 93-107.
Barnas, C., Whitworth, A. B., & Fleischhacker, W. W. (1993). Are patterns of benzodiazepine
use predictable? A follow-up study of benzodiazepine users. Psychopharmacology,
111(3), 301-305.
Bastien, C. H., Vallieres, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index
as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297-307.
Bazargan, M., Mian, N., Cobb, S., Vargas, R., & Assari, S. (2019). Insomnia symptoms among
African-American older adults in economically disadvantaged areas of South Los
Angeles. Brain Sciences, 9(11).
Bean, D. J., Johnson, M. H., & Kydd, R. R. (2014). Relationships between psychological factors,
pain, and disability in complex regional pain syndrome and low back pain. The Clinical
Journal of Pain, 30(8), 647-653.
Beard, C., & Björgvinsson, T. (2014). Beyond generalized anxiety disorder: psychometric
properties of the GAD-7 in a heterogeneous psychiatric sample. Journal of Anxiety
Disorders, 28(6), 547-552.
Bergtold, J. S., Yeager, E. A., & Featherstone, A. M. (2011, July 24-26). Sample size and
robustness of inferences from logistic regression in the presence of nonlinearity and
multicollinearity Agricultural and Applied Economics Association 2011 Annual Meeting,
Pittsburgh, PA.

53
Berinsky, A. J., Huber, G. A., & Lenz, G. S. (2012). Evaluating online labor markets for
experimental research: Amazon.com's Mechanical Turk. Political Analysis, 20(3), 351368.
Beymer, M. R., Holloway, I. W., & Grov, C. (2018). Comparing self-reported demographic and
sexual behavioral factors among men who have sex with men recruited through
Mechanical Turk, Qualtrics, and a HIV/STI clinic-based sample: Implications for
researchers and providers. Archives of Sexual Behavior, 47(1), 133-142.
Black, J. C., Rockhill, K., Forber, A., Amioka, E., May, K. P., Haynes, C. M., . . . Dart, R. C.
(2019). An online survey for pharmacoepidemiological investigation (Survey of NonMedical Use of Prescription Drugs Program): Validation study. Journal of Medical
Internet Research, 21(10), e15830.
Blanco, C., Han, B., Jones, C. M., Johnson, K., & Compton, W. M. (2018). Prevalence and
correlates of benzodiazepine use, misuse, and use disorders among adults in the United
States. Journal of Clinical Psychiatry, 79(6).
Boehnke, K. F., McAfee, J., Ackerman, J. M., & Kruger, D. J. (2021). Medication and substance
use increases among people using cannabis medically during the COVID-19 pandemic.
International Journal of Drug Policy, 92, 103053.
Bohn, M. J., Babor, T. F., & Kranzler, H. R. (1995). The Alcohol Use Disorders Identification
Test (AUDIT): validation of a screening instrument for use in medical settings. Journal
of Studies on Alcohol, 56(4), 423-432.
Bolger, N., & Laurenceau, J.-P. (2013). Intensive longitudinal methods: An introduction to diary
and experience sampling research. Guilford Press.

54
Boonstra, A. M., Reneman, M. F., Stewart, R. E., Post, M. W., & Schiphorst Preuper, H. R.
(2013). Life satisfaction in patients with chronic musculoskeletal pain and its predictors.
Quality of Life Research, 22(1), 93-101.
Box, G. E., & Tidwell, P. W. (1962). Transformation of the independent variables.
Technometrics, 4(4), 531-550.
Boyd, C. J., Austic, E., Epstein-Ngo, Q., Veliz, P. T., & McCabe, S. E. (2015). A prospective
study of adolescents' nonmedical use of anxiolytic and sleep medication. Psychology of
Addictive Behaviors, 29(1), 184-191.
Brandt, J., Alkabanni, W., Alessi-Severini, S., & Leong, C. (2018). Translating benzodiazepine
utilization data into meaningful population exposure: Integration of two metrics for
improved reporting. Clinical Drug Investigation, 38(7), 565-572.
Brennan, P. L., Schutte, K. K., & Moos, R. H. (2005). Pain and use of alcohol to manage pain:
prevalence and 3-year outcomes among older problem and non-problem drinkers.
Addiction, 100(6), 777-786.
Breslau, N., & Johnson, E. O. (2000). Predicting smoking cessation and major depression in
nicotine-dependent smokers. American journal of public health, 90(7), 1122-1127.
Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and dependence.
Australian Prescriber, 38(5), 152-155.
Briggs, A. M., Woolf, A. D., Dreinhofer, K., Homb, N., Hoy, D. G., Kopansky-Giles, D., . . .
March, L. (2018). Reducing the global burden of musculoskeletal conditions. Bulletin of
the World Health Organization, 96(5), 366-368.

55
Burling, A. S., & Burling, T. A. (2003). A comparison of self-report measures of nicotine
dependence among male drug/alcohol-dependent cigarette smokers. Nicotine & Tobacco
Research, 5(5), 625-633.
Butler, S. F., Budman, S. H., Fanciullo, G. J., & Jamison, R. N. (2010). Cross validation of the
Current Opioid Misuse Measure to monitor chronic pain patients on opioid therapy.
Clinical Journal of Pain, 26(9), 770-776.
Butler, S. F., Budman, S. H., Fernandez, K. C., Houle, B., Benoit, C., Katz, N., & Jamison, R. N.
(2007). Development and validation of the Current Opioid Misuse Measure. Pain, 130(12), 144-156.
Cameron, J. J., & Stinson, D. A. (2019). Gender (mis)measurement: Guidelines for respecting
gender diversity in psychological research. Social and Personality Psychology Compass,
13(11), e12506.
Campbell, C. M., Buenaver, L. F., Finan, P., Bounds, S. C., Redding, M., McCauley, L., . . .
Smith, M. T. (2015). Sleep, pain catastrophizing, and central sensitization in knee
osteoarthritis patients with and without insomnia. Arthritis Care & Research, 67(10),
1387-1396.
Carey, K. B., Carey, M. P., Maisto, S. A., & Henson, J. M. (2006). Brief motivational
interventions for heavy college drinkers: A randomized controlled trial. Journal of
consulting and clinical psychology, 74(5), 943-954.
Chandler, J., & Shapiro, D. (2016). Conducting clinical research using crowdsourced
convenience samples. Annual Review of Clinical Psychology, 12, 53-81.

56
Chandler, J. J., & Paolacci, G. (2017). Lie for a dime: When most prescreening responses are
honest but most study participants are impostors. Social Psychological and Personality
Science, 8(5), 500-508.
Cheng, S., Siddiqui, T. G., Gossop, M., Kristoffersen, E. S., & Lundqvist, C. (2019). The
Severity of Dependence Scale detects medication misuse and dependence among
hospitalized older patients. BMC Geriatrics, 19(1), 174.
Ciccone, D. S., Chandler, H. K., & Kline, A. (2010). Catastrophic appraisal of acute and chronic
pain in a population sample of New Jersey National Guard troops. Clinical Journal of
Pain, 26(8), 712-721.
Collins, R. L., Parks, G. A., & Marlatt, G. A. (1985). Social determinants of alcohol
consumption: the effects of social interaction and model status on the self-administration
of alcohol. Journal of consulting and clinical psychology, 53(2), 189.
Cox, W. M., & Klinger, E. (1988). A motivational model of alcohol use. Journal of Abnormal
Psychology, 97(2), 168-180.
Cunningham, J. A., Godinho, A., & Kushnir, V. (2017a). Using Mechanical Turk to recruit
participants for internet intervention research: Experience from recruitment for four trials
targeting hazardous alcohol consumption. BMC Medical Research Methodology, 17(1),
156.
Cunningham, J. L., Craner, J. R., Evans, M. M., & Hooten, W. M. (2017b). Benzodiazepine use
in patients with chronic pain in an interdisciplinary pain rehabilitation program. Journal
of Pain Research, 10, 311-317.

57
Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., . . . Helmick, C. (2018).
Prevalence of chronic pain and high-impact chronic pain among adults—United States,
2016. Morbidity and Mortality Weekly Report, 67(36), 1001.
Dasgupta, N., Funk, M. J., Proescholdbell, S., Hirsch, A., Ribisl, K. M., & Marshall, S. (2016).
Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain
Medicine, 17(1), 85-98.
Daubresse, M., Chang, H. Y., Yu, Y., Viswanathan, S., Shah, N. D., Stafford, R. S., . . .
Alexander, G. C. (2013). Ambulatory diagnosis and treatment of nonmalignant pain in
the United States, 2000-2010. Medical Care, 51(10), 870-878.
Day, B. F., & Rosenthal, G. L. (2019). Social isolation proxy variables and prescription opioid
and benzodiazepine misuse among older adults in the U.S.: A cross-sectional analysis of
data from the National Survey on Drug Use and Health, 2015–2017. Drug and Alcohol
Dependence, 204, 107518.
Day, M. A., & Thorn, B. E. (2010). The relationship of demographic and psychosocial variables
to pain-related outcomes in a rural chronic pain population. Pain, 151(2), 467-474.
de las Cuevas, C., Sanz, E. J., de la Fuente, J. A., Padilla, J., & Berenguer, J. C. (2000). The
Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence:
SDS validation study. Addiction, 95(2), 245-250.
Dellemijn, P. L., & Fields, H. L. (1994). Do benzodiazepines have a role in chronic pain
management? Pain, 57(2), 137-152.
Dimeff, L. A. (1999). Brief Alcohol Screening and Intervention for College Students (BASICS):
A Harm Reduction Approach. Guilford Publications.

58
Ditre, J. W., & Brandon, T. H. (2008). Pain as a motivator of smoking: effects of pain induction
on smoking urge and behavior. Journal of Abnormal Psychology, 117(2), 467-472.
Ditre, J. W., Heckman, B. W., Butts, E. A., & Brandon, T. H. (2010). Effects of expectancies and
coping on pain-induced motivation to smoke. Journal of Abnormal Psychology, 119(3),
524-533.
Ditre, J. W., Zale, E. L., & LaRowe, L. R. (2019). A reciprocal model of pain and substance use:
Transdiagnostic considerations, clinical implications, and future directions. Annual
Review of Clinical Psychology, 15, 503-528.
Dublin, S., Walker, R. L., Jackson, M. L., Nelson, J. C., Weiss, N. S., Von Korff, M., & Jackson,
L. A. (2011). Use of opioids or benzodiazepines and risk of pneumonia in older adults: a
population-based case-control study. Journal of the American Geriatrics Society, 59(10),
1899-1907.
Dunn, K. E., Barrett, F. S., Yepez-Laubach, C., Meyer, A. C., Hruska, B. J., Sigmon, S. C., . . .
Bigelow, G. E. (2016). Brief Opioid Overdose Knowledge (BOOK): A questionnaire to
assess overdose knowledge in individuals who use illicit or prescribed opioids. Journal of
Addiction Medicine, 10(5), 314-323.
Durbin, J., & Watson, G. S. (1951). Testing for serial correlation in least squares regression. II.
Biometrika, 38(1-2), 159-178.
Dwyer, R. (2008). Privileging pleasure: Temazepam injection in a heroin marketplace.
International Journal of Drug Policy, 19(5), 367-374.
Edwards, R. R., Cahalan, C., Mensing, G., Smith, M., & Haythornthwaite, J. A. (2011). Pain,
catastrophizing, and depression in the rheumatic diseases. Nature Reviews Rheumatology,
7(4), 216-224.

59
Elman, I., & Borsook, D. (2016). Common brain mechanisms of chronic pain and addiction.
Neuron, 89(1), 11-36.
Etter, J. F. (2005). A comparison of the content-, construct- and predictive validity of the
Cigarette Dependence Scale and the Fagerstrom Test for Nicotine Dependence. Drug and
Alcohol Dependence, 77(3), 259-268.
Fatséas, M., Lavie, E., Denis, C., & Auriacombe, M. (2009). Self-perceived motivation for
benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent
patients. Journal of Substance Abuse Treatment, 37(4), 407-411.
Fayaz, A., Ayis, S., Panesar, S. S., Langford, R. M., & Donaldson, L. J. (2016). Assessing the
relationship between chronic pain and cardiovascular disease: A systematic review and
meta-analysis. Scandinavian Journal of Pain, 13, 76-90.
Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., 3rd.
(2009). Sex, gender, and pain: a review of recent clinical and experimental findings.
Journal of Pain, 10(5), 447-485.
Gaskin, D. J., & Richard, P. (2012). The economic costs of pain in the United States. Journal of
Pain, 13(8), 715-724.
George, D., & Mallery, P. (2011). SPSS for Windows Step by Step: A Simple Study Guide and
Reference, 17.0 update, 10/e. Pearson Education India.
Goesling, J., Clauw, D. J., & Hassett, A. L. (2013). Pain and depression: an integrative review of
neurobiological and psychological factors. Current Psychiatry Reports, 15(12), 421.
Granot, M., & Ferber, S. G. (2005). The roles of pain catastrophizing and anxiety in the
prediction of postoperative pain intensity: A prospective study. The Clinical Journal of
Pain, 21(5).

60
Griffin, C. E., 3rd, Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013). Benzodiazepine
pharmacology and central nervous system-mediated effects. The Ochsner Journal, 13(2),
214-223.
Gudin, J. A., Mogali, S., Jones, J. D., & Comer, S. D. (2013). Risks, management, and
monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgraduate
Medical Journal, 125(4), 115-130.
Guina, J., & Merrill, B. (2018). Benzodiazepines I: Upping the care on downers: The evidence of
risks, benefits and alternatives. Clinical Medicine, 7(2).
Gureje, O., Von Korff, M., Simon, G. E., & Gater, R. (1998). Persistent pain and well-being: a
World Health Organization study in primary care. JAMA, 280(2), 147-151.
Häuser, W., Wolfe, F., Henningsen, P., Schmutzer, G., Brähler, E., & Hinz, A. (2014). Untying
chronic pain: prevalence and societal burden of chronic pain stages in the general
population - a cross-sectional survey. BMC Public Health, 14(1), 352.
Hayashi, K., Suwannawong, P., Ti, L., Kaplan, K., Wood, E., & Kerr, T. (2013). High rates of
midazolam injection and associated harms in Bangkok, Thailand. Addiction, 108(5), 944952.
Hayes, A. F. (2017). Introduction to Mediation, Moderation, and Conditional Process Analysis:
A Regression-Based Approach. Guilford Publications.
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., Rickert, W., & Robinson, J. (1989).
Measuring the heaviness of smoking: using self-reported time to the first cigarette of the
day and number of cigarettes smoked per day. British Journal of Addiction, 84(7), 791799.

61
Herrero Babiloni, A., De Koninck, B. P., Beetz, G., De Beaumont, L., Martel, M. O., & Lavigne,
G. J. (2020). Sleep and pain: recent insights, mechanisms, and future directions in the
investigation of this relationship. Journal of Neural Transmission (Vienna), 127(4), 647660.
Holm, E., Fosbol, E., Pedersen, H., Jensen, T. B., Nielsen, M., Weeke, P., . . . Torp-Pedersen, C.
(2012). Benzodiazepine use in Denmark 1997–2008. European Geriatric Medicine, 3(5),
299-303.
Huang, J. L., Curran, P. G., Keeney, J., Poposki, E. M., & DeShon, R. P. (2012). Detecting and
deterring insufficient effort responding to surveys. Journal of Business and Psychology,
27(1), 99-114.
Hughes, J. L., Camden, A. A., & Yangchen, T. (2016). Rethinking and updating demographic
questions: Guidance to improve descriptions of research samples. Psi Chi Journal of
Psychological Research, 21(3), 138-151.
Huhn, A. S., Garcia-Romeu, A. P., & Dunn, K. E. (2018). Opioid overdose education for
individuals prescribed opioids for pain management: Randomized comparison of two
computer-based interventions. Frontiers in Psychiatry, 9, 34.
Hydock, C. (2018). Assessing and overcoming participant dishonesty in online data collection.
Behavior Research Methods, 50(4), 1563-1567.
IBM Corp. (2019). IBM SPSS Statistics for Macintosh, Version 26.0. In Armonk, NY: IBM
Corp.
Ikard, F. F., Green, D. E., & Horn, D. (1969). A scale to differentiate between types of smoking
as related to the management of affect. International Journal of the Addictions, 4(4), 649659.

62
Institute of Medicine. (2011). Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education, and Research. National Academies Press.
Isacson, D. (1997). Long-term benzodiazepine use: factors of importance and the development of
individual use patterns over time--a 13-year follow-up in a Swedish community. Social
Science & Medicine, 44(12), 1871-1880.
Jeffery, M. M., Hooten, W. M., Jena, A. B., Ross, J. S., Shah, N. D., & Karaca-Mandic, P.
(2019). Rates of physician coprescribing of opioids and benzodiazepines after the release
of the Centers for Disease Control and Prevention guidelines in 2016. JAMA Network
Open, 2(8), e198325.
Johnson, P. S., Herrmann, E. S., & Johnson, M. W. (2015). Opportunity costs of reward delays
and the discounting of hypothetical money and cigarettes. Journal of the Experimental
Analysis of Behavior, 103(1), 87-107.
Johnston, L. D., Miech, R. A., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick,
M. E. (2018). Monitoring the Future national survey results on drug use, 1975-2017:
Overview, key findings on adolescent drug use. I. f. S. Research.
Jones, J. D., Mogali, S., & Comer, S. D. (2012). Polydrug abuse: A review of opioid and
benzodiazepine combination use. Drug and Alcohol Dependence, 125(1), 8-18.
Kandel, D. B., Hu, M. C., Griesler, P., & Wall, M. (2017). Increases from 2002 to 2015 in
prescription opioid overdose deaths in combination with other substances. Drug and
Alcohol Dependence, 178, 501-511.
Kaufmann, C. N., Spira, A. P., Depp, C. A., & Mojtabai, R. (2018). Long-term use of
benzodiazepines and nonbenzodiazepine hypnotics, 1999-2014. Psychiatric Services,
69(2), 235-238.

63
Kim, H. S., McCarthy, D. M., Hoppe, J. A., Mark Courtney, D., & Lambert, B. L. (2018).
Emergency department provider perspectives on benzodiazepine-opioid coprescribing: A
qualitative study. Academic Emergency Medicine, 25(1), 15-24.
King, S. A., & Strain, J. J. (1990). Benzodiazepine use by chronic pain patients. Clinical Journal
of Pain, 6(2), 143-147.
Kneeland, E. T., Griffin, M. L., Taghian, N., Weiss, R. D., & McHugh, R. K. (2019).
Associations between pain catastrophizing and clinical characteristics in adults with
substance use disorders and co-occurring chronic pain. The American Journal of Drug
and Alcohol Abuse, 45(5), 488-494.
Kokkevi, A., Fotiou, A., Arapaki, A., & Richardson, C. (2008). Prevalence, patterns, and
correlates of tranquilizer and sedative use among European adolescents. Journal of
Adolescent Health, 43(6), 584-592.
Kosiba, J. D., Zale, E. L., & Ditre, J. W. (2018). Associations between pain intensity and urge to
smoke: Testing the role of negative affect and pain catastrophizing. Drug and Alcohol
Dependence, 187, 100-108.
Lankenau, S. E., Teti, M., Silva, K., Bloom, J. J., Harocopos, A., & Treese, M. (2012). Patterns
of prescription drug misuse among young injection drug users. Journal of Urban Health,
89(6), 1004-1016.
Larochelle, M. R., Zhang, F., Ross-Degnan, D., & Wharam, J. F. (2015). Trends in opioid
prescribing and co-prescribing of sedative hypnotics for acute and chronic
musculoskeletal pain: 2001–2010. Pharmacoepidemiology and Drug Safety, 24(8), 885892.

64
LaRowe, L. R., Maisto, S. A., & Ditre, J. W. (2021). A measure of expectancies for alcohol
analgesia: Preliminary factor analysis, reliability, and validity. Addictive Behaviors, 116,
106822.
Larson, M. J., Paasche-Orlow, M., Cheng, D. M., Lloyd-Travaglini, C., Saitz, R., & Samet, J. H.
(2007). Persistent pain is associated with substance use after detoxification: a prospective
cohort analysis. Addiction, 102(5), 752-760.
Lawton, J., & Simpson, J. (2009). Predictors of alcohol use among people experiencing chronic
pain. Psychology, Health & Medicine, 14(4), 487-501.
Lembke, A., Papac, J., & Humphreys, K. (2018). Our other prescription drug problem. New
England Journal of Medicine, 378(8), 693-695.
Liebrenz, M., Schneider, M., Buadze, A., Gehring, M. T., Dube, A., & Caflisch, C. (2015). Highdose benzodiazepine dependence: A qualitative study of patients' perceptions on
initiation, reasons for use, and obtainment. PLoS One, 10(11), e0142057.
Liebschutz, J. M., Saitz, R., Weiss, R. D., Averbuch, T., Schwartz, S., Meltzer, E. C., . . . Samet,
J. H. (2010). Clinical factors associated with prescription drug use disorder in urban
primary care patients with chronic pain. The Journal of Pain, 11(11), 1047-1055.
Limandri, B. J. (2018). Benzodiazepine use: The underbelly of the opioid epidemic. Journal of
Psychosocial Nursing and Mental Health Services, 56(6), 11-15.
Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y.
(2008). Validation and standardization of the Generalized Anxiety Disorder Screener
(GAD-7) in the general population. Medical Care, 46(3), 266-274.

65
Martel, M. O., Wasan, A. D., Jamison, R. N., & Edwards, R. R. (2013). Catastrophic thinking
and increased risk for prescription opioid misuse in patients with chronic pain. Drug and
Alcohol Dependence, 132(1-2), 335-341.
Mateu-Gelabert, P., Jessell, L., Goodbody, E., Kim, D., Gile, K., Teubl, J., . . . Guarino, H.
(2017). High enhancer, downer, withdrawal helper: Multifunctional nonmedical
benzodiazepine use among young adult opioid users in New York City. International
Journal of Drug Policy, 46, 17-27.
Maust, D. T., Lin, L. A., & Blow, F. C. (2019). Benzodiazepine use and misuse among adults in
the United States. Psychiatric Services, 70(2), 97-106.
McCabe, S. E. (2005). Correlates of nonmedical use of prescription benzodiazepine anxiolytics:
results from a national survey of U.S. college students. Drug and Alcohol Dependence,
79(1), 53-62.
McCabe, S. E., Boyd, C. J., & Teter, C. J. (2009). Subtypes of nonmedical prescription drug
misuse. Drug and Alcohol Dependence, 102(1), 63-70.
McCabe, S. E., & Cranford, J. A. (2012). Motivational subtypes of nonmedical use of
prescription medications: Results from a national study. Journal of Adolescent Health,
51(5), 445-452.
McCabe, S. E., West, B. T., Cranford, J. A., Ross-Durow, P., Young, A., Teter, C. J., & Boyd, C.
J. (2011). Medical misuse of controlled medications among adolescents. Archives of
Pediatrics & Adolescent Medicine, 165(8), 729-735.
McCracken, L. M., Zayfert, C., & Gross, R. T. (1992). The Pain Anxiety Symptoms Scale:
development and validation of a scale to measure fear of pain. Pain, 50(1), 67-73.

66
McDermott, K. A., Joyner, K. J., Hakes, J. K., Okey, S. A., & Cougle, J. R. (2018). Pain
interference and alcohol, nicotine, and cannabis use disorder in a national sample of
substance users. Drug and Alcohol Dependence, 186, 53-59.
McHugh, R. K., Kneeland, E. T., Edwards, R. R., Jamison, R., & Weiss, R. D. (2020a). Pain
catastrophizing and distress intolerance: prediction of pain and emotional stress
reactivity. Journal of Behavioral Medicine, 43(4), 623-629.
McHugh, R. K., Votaw, V. R., Bogunovic, O., Karakula, S. L., Griffin, M. L., & Weiss, R. D.
(2017). Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid
use disorder. Addictive Behaviors, 65, 283-288.
McHugh, R. K., Votaw, V. R., Taghian, N. R., Griffin, M. L., & Weiss, R. D. (2020b).
Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and
patterns of use. Journal of Substance Abuse Treatment, 117, 108061.
Meltzer, E. C., Rybin, D., Saitz, R., Samet, J. H., Schwartz, S. L., Butler, S. F., & Liebschutz, J.
M. (2011). Identifying prescription opioid use disorder in primary care: diagnostic
characteristics of the Current Opioid Misuse Measure (COMM). Pain, 152(2), 397-402.
Messina, B. G., Dutta, N. M., Silvestri, M. M., Diulio, A. R., Garza, K. B., Murphy, J. G., &
Correia, C. J. (2016). Modeling motivations for non-medical use of prescription drugs.
Addictive Behaviors, 52, 46-51.
Michelini, S., Cassano, G. B., Frare, F., & Perugi, G. (1996). Long-term use of benzodiazepines:
tolerance, dependence and clinical problems in anxiety and mood disorders.
Pharmacopsychiatry, 29(4), 127-134.
Mikel, C., Pesce, A. J., Rosenthal, M., & West, C. (2012). Therapeutic monitoring of
benzodiazepines in the management of pain: Current limitations of point of care

67
immunoassays suggest testing by mass spectrometry to assure accuracy and improve
patient safety. Clinica Chimica Acta, 413(15), 1199-1202.
Mogil, J. S. (2012). Sex differences in pain and pain inhibition: multiple explanations of a
controversial phenomenon. Nature Reviews Neuroscience, 13(12), 859-866.
Morasco, B. J., Turk, D. C., Donovan, D. M., & Dobscha, S. K. (2013). Risk for prescription
opioid misuse among patients with a history of substance use disorder. Drug and Alcohol
Dependence, 127(1), 193-199.
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index:
Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep,
34(5), 601-608.
Moskal, D., Maisto, S. A., De Vita, M., & Ditre, J. W. (2018). Effects of experimental pain
induction on alcohol urge, intention to consume alcohol, and alcohol demand.
Experimental and Clinical Psychopharmacology, 26(1), 65-76.
Motta-Ochoa, R., Bertrand, K., Arruda, N., Jutras-Aswad, D., & Roy, É. (2017). “I love having
benzos after my coke shot”: The use of psychotropic medication among cocaine users in
downtown Montreal. International Journal of Drug Policy, 49, 15-23.
Myers, R. H. (1990). Classical and modern regression with applications (Vol. 2). Duxbury
Press.
Nattala, P., Leung, K. S., Abdallah, A. B., & Cottler, L. B. (2011). Heavy use versus less heavy
use of sedatives among non-medical sedative users: Characteristics and correlates.
Addictive Behaviors, 36(1-2), 103-109.

68
Nicholson, H. L., & Ford, J. A. (2018). Correlates of prescription opioid misuse among Black
adults: Findings from the 2015 National Survey on Drug Use and Health. Drug and
Alcohol Dependence, 186, 264-267.
Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., . . . Degenhardt, L.
(2015). Benzodiazepine use among chronic pain patients prescribed opioids: associations
with pain, physical and mental health, and health service utilization. Pain Medicine,
16(2), 356-366.
Nieto, S. J., Green, R., Grodin, E. N., Cahill, C. M., & Ray, L. A. (2021). Pain catastrophizing
predicts alcohol craving in heavy drinkers independent of pain intensity. Drug and
Alcohol Dependence, 218, 108368.
Ogbu, U. C., Lotfipour, S., & Chakravarthy, B. (2015). Polysubstance abuse: alcohol, opioids
and benzodiazepines require coordinated engagement by society, patients, and
physicians. Western Journal of Emergency Medicine, 16(1), 76-79.
Olfson, M., King, M., & Schoenbaum, M. (2015). Benzodiazepine use in the United States.
JAMA Psychiatry, 72(2), 136-142.
Osman, A., Barrios, F. X., Gutierrez, P. M., Kopper, B. A., Merrifield, T., & Grittmann, L.
(2000). The Pain Catastrophizing Scale: Further psychometric evaluation with adult
samples. Journal of Behavioral Medicine, 23(4), 351-365.
Otte, J. L., Bakoyannis, G., Rand, K. L., Ensrud, K. E., Guthrie, K. A., Joffe, H., . . . Carpenter,
J. S. (2019). Confirmatory factor analysis of the Insomnia Severity Index (ISI) and
invariance across race: a pooled analysis of MsFLASH data. Menopause, 26(8), 850-855.
Pandraud-Riguet, I., Bonnet-Zamponi, D., Bourcier, E., Buyse, M., Laribe-Caget, S., Frémont,
P., . . . Fernandez, C. (2017). Monitoring of potentially inappropriate prescriptions in

69
older inpatients: A French multicenter study. Journal of the American Geriatrics Society,
65(12), 2713-2719.
Paolacci, G., & Chandler, J. (2014). Inside the Turk: Understanding Mechanical Turk as a
participant pool. Current Directions in Psychological Science, 23(3), 184-188.
Parr, J. M., Kavanagh, D. J., Young, R. M., & McCafferty, K. (2006). Views of general
practitioners and benzodiazepine users on benzodiazepines: A qualitative analysis. Social
Science & Medicine, 62(5), 1237-1249.
Pergolizzi, J. V., & LeQuang, J. A. (2020). Reappraising the use of benzodiazepines in chronic
pain patients. Postgraduate Medical Journal, 1-3.
Petersen, K. K., Jensen, M. B., Graven-Nielsen, T., Hauerslev, L. V., Arendt-Nielsen, L., &
Rathleff, M. S. (2020). Pain catastrophizing, self-reported disability, and temporal
summation of pain predict self-reported pain in low back pain patients 12 weeks after
general practitioner consultation: A prospective cohort study. Clinical Journal of Pain,
36(10), 757-763.
Phillips, C. J. (2009). The cost and burden of chronic pain. Reviews in Pain, 3(1), 2-5.
Puckett, J. A., Brown, N. C., Dunn, T., Mustanski, B., & Newcomb, M. E. (2020). Perspectives
from transgender and gender diverse people on how to ask about gender. LGBT Health,
7(6), 305-311.
Quartana, P. J., Campbell, C. M., & Edwards, R. R. (2009). Pain catastrophizing: a critical
review. Expert Review of Neurotherapeutics, 9(5), 745-758.
Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., . . . Vader, K. (2020).
The revised International Association for the Study of Pain definition of pain: Concepts,
challenges, and compromises. Pain, 161(9), 1976-1982.

70
Reese, E. D., & Veilleux, J. C. (2016). Relationships between craving beliefs and abstinence
self-efficacy are mediated by smoking motives and moderated by nicotine dependence.
Nicotine & Tobacco Research, 18(1), 48-55.
Reinert, D. F., & Allen, J. P. (2002). The Alcohol Use Disorders Identification Test (AUDIT): A
review of recent research. Alcoholism: Clinical and Experimental Research, 26(2), 272279.
Rigg, K. K., & Ford, J. A. (2014). The misuse of benzodiazepines among adolescents:
Psychosocial risk factors in a national sample. Drug and Alcohol Dependence, 137, 137142.
Ruchensky, J. R., Donnellan, M. B., & Edens, J. F. (2018). Development and initial validation of
the HEXACO-Triarchic Scales. Psychological Assessment, 30(12), 1560-1566.
Schmidt, C. O., Raspe, H., & Kohlmann, T. (2010). Graded back pain revisited - do latent
variable models change our understanding of severe back pain in the general population?
Pain, 149(1), 50-56.
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008). Clinical guideline for
the evaluation and management of chronic insomnia in adults. Journal of Clinical Sleep
Medicine, 4(5), 487-504.
Sharpe Wessling, K., Huber, J., & Netzer, O. (2017). MTurk character misrepresentation:
Assessment and solutions. Journal of Consumer Research, 44(1), 211-230.
Simons, L. E., Elman, I., & Borsook, D. (2014). Psychological processing in chronic pain: a
neural systems approach. Neuroscience & Biobehavioral Reviews, 39, 61-78.

71
Sirdifield, C., Chipchase, S. Y., Owen, S., & Siriwardena, A. N. (2017). A systematic review and
meta-synthesis of patients' experiences and perceptions of seeking and using
benzodiazepines and z-drugs: Towards safer prescribing. Patient, 10(1), 1-15.
Smith, D., Wilkie, R., Croft, P., Parmar, S., & McBeth, J. (2018). Pain and mortality:
mechanisms for a relationship. Pain, 159(6), 1112-1118.
Smith, T. W., Davern, M., Freese, J., & Morgan, S. L. (2019). General Social Surveys, 19722018: Cumulative Codebook. Chicago: NORC.
Soyka, M. (2017). Treatment of benzodiazepine dependence. The New England Journal of
Medicine, 376(12), 1147-1157.
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for
assessing Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine,
166(10), 1092-1097.
Stein, M. D., Kanabar, M., Anderson, B. J., Lembke, A., & Bailey, G. L. (2016). Reasons for
benzodiazepine use among persons seeking opioid detoxification. Journal of Substance
Abuse Treatment, 68, 57-61.
Sterniczuk, R., & Whelan, J. (2016). Cannabis use among Canadian Armed Forces Veterans.
Journal of Military, Veteran and Family Health, 2(2), 43-52.
Strickland, J. C., Lile, J. A., & Stoops, W. W. (2019a). Contribution of cannabis-related cues to
concurrent reinforcer choice in humans. Drug and Alcohol Dependence, 199, 85-91.
Strickland, J. C., Lile, J. A., & Stoops, W. W. (2019b). Evaluating non-medical prescription
opioid demand using commodity purchase tasks: Test-retest reliability and incremental
validity. Psychopharmacology (Berlin), 236(9), 2641-2652.

72
Strickland, J. C., & Stoops, W. W. (2015). Perceptions of research risk and undue influence:
Implications for ethics of research conducted with cocaine users. Drug and Alcohol
Dependence, 156, 304-310.
Strickland, J. C., & Stoops, W. W. (2017). Stimulus selectivity of drug purchase tasks: A
preliminary study evaluating alcohol and cigarette demand. Experimental and Clinical
Psychopharmacology, 25(3), 198-207.
Strickland, J. C., & Stoops, W. W. (2018). Feasibility, acceptability, and validity of
crowdsourcing for collecting longitudinal alcohol use data. Journal of the Experimental
Analysis of Behavior, 110(1), 136-153.
Strickland, J. C., & Stoops, W. W. (2019). The use of crowdsourcing in addiction science
research: Amazon Mechanical Turk. Experimental and Clinical Psychopharmacology,
27(1), 1-18.
Substance Abuse and Mental Health Services Administration. (2018). 2018 National Survey on
Drug Use and Health: Methodological Summary and Definitions. Rockville MD: Center
for Behavioral Health Statistics and Quality.
Sullivan, M. J. L., Bishop, S. R., & Pivik, J. (1995). The Pain Catastrophizing Scale:
Development and validation. Psychological Assessment, 7(4), 524-532.
Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017).
Association between concurrent use of prescription opioids and benzodiazepines and
overdose: retrospective analysis. Bmj, 356, j760.
Torrance, N., Mansoor, R., Wang, H., Gilbert, S., Macfarlane, G. J., Serpell, M., . . . Colvin, L.
(2018). Association of opioid prescribing practices with chronic pain and benzodiazepine

73
co-prescription: a primary care data linkage study. British Journal of Anaesthesia, 120(6),
1345-1355.
Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., . . . Wang, S. J. (2015).
A classification of chronic pain for ICD-11. Pain, 156(6), 1003-1007.
Turk, D. C., & Melzack, R. (2011). Handbook of Pain Assessment. Guilford Press.
Victor, G. A., Strickland, J. C., Kheibari, A. Z., & Flaherty, C. (2020). A mixed-methods
approach to understanding overdose risk-management strategies among a nationwide
convenience sample. International Journal of Drug Policy, 86, 102973.
Vogel, M., Knöpfli, B., Schmid, O., Prica, M., Strasser, J., Prieto, L., . . . Dürsteler-MacFarland,
K. M. (2013). Treatment or “high”: Benzodiazepine use in patients on injectable heroin
or oral opioids. Addictive Behaviors, 38(10), 2477-2484.
Von Korff, M. (2011). Assessment of chronic pain in epidemiological and health services
research: Empirical bases and new directions. In Handbook of Pain Assessment, 3rd ed.
(pp. 455-473). The Guilford Press.
Von Korff, M., Ormel, J., Keefe, F. J., & Dworkin, S. F. (1992). Grading the severity of chronic
pain. Pain, 50(2), 133-149.
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019). The epidemiology of
benzodiazepine misuse: A systematic review. Drug and Alcohol Dependence, 200, 95114.
Votaw, V. R., McHugh, R. K., Vowles, K. E., & Witkiewitz, K. (2020). Patterns of
polysubstance use among adults with tranquilizer misuse. Substance Use & Misuse,
55(6), 861-870.

74
Walters, K., Christakis, D. A., & Wright, D. R. (2018). Are Mechanical Turk worker samples
representative of health status and health behaviors in the U.S.? PLoS One, 13(6),
e0198835.
Wiens, T. K., & Walker, L. J. (2015). The chronic disease concept of addiction: Helpful or
harmful? Addiction Research & Theory, 23(4), 309-321.
Williams, F., Mahfouz, C., Bonney, A., Pearson, R., Seidel, B., Dijkmans-Hadley, B., & Ivers,
R. (2016). A circle of silence: The attitudes of patients older than 65 years of age to
ceasing long-term sleeping tablets. Australian Family Physician, 45(7), 506-511.
Wright, S. L. (2020). Limited utility for benzodiazepines in chronic pain management: A
narrative review. Advances in Therapy, 37(6), 2604-2619.
Yelin, E., Cisternas, M., Trupin, L., & Gansky, S. (2014). Costs of musculoskeletal diseases in
the United States, 1996-2011: Population growth, population aging, health care
utilization, or prices? Arthritis and Rheumatology, 66, S41-S42.

75
VITA
NAME OF AUTHOR: Emma Carnes Lape

CONTACT INFORMATION:
430 Huntington Hall
Syracuse, NY 13244

GRADUATE AND UNDERGRADUATE SCHOOLS ATTENDED:
Syracuse University, Syracuse, NY
Dartmouth College, Hanover, NH

DEGREES AWARDED:
Bachelor of Arts in Classical Languages and Literatures, 2016, Dartmouth College

